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ABSTRACT 
Fibroblast growth factors (FGFs) are a family of proteins whose signaling in cells 
play important roles in cell growth and development, cell differentiation, and 
angiogenesis [Powers, et al., 2000]. Investigations into the role ofFGF in cell growth and 
differentiation in Xenopus laevis embryos led to the identification of a novel immediate-
early gene, or initial target, of FGF signal transduction, which was later named mesoderm 
induction early response 1 (mi-erl) [Paterno, et al., 1997]. A human orthologue ofxmi-
erl, hmi-erl, was also cloned in our laboratory [Paterno, et al., 1998; Paterno, et al., 
2002]. hMI-ER1 was found to be consistently expressed at low levels in normal human 
tissues, however, breast carcinoma cell lines and tumour tissue samples displayed 
elevated levels, indicating that hMI-ER1 may have a role in the neoplastic state (Paterno, 
et al., 1998; Paterno, et al., 2002]. 
Examination of the protein structure ofhMI-ERl revealed the presence of a 
number of protein interacting motifs, namely an acidic activation domain, ELM2 and 
SANT domains. Each of these motifs are present in both hMI-ERla and hMI-ERl~ 
isoforms. Notably, the hMI-ERla isoform also contains an LXXLL motif (L represents 
the amino acid leucine and X can be any amino acid), a domain not found in hMI-ERl~ 
but commonly found in nuclear hormone receptor interacting proteins. Therefore, my 
hypothesis is that hMI-ERl a is involved in protein-protein interactions involving nuclear 
hormone receptors. The finding that hMI-ERl recruits HDAC (histone deacetylase) 
activity through the ELM2 domain [Ding, et al., 2002], indicates that hMI-ERl is 
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involved in transcriptional regulation, and will therefore, also likely play a role in the 
regulation of transcription by nuclear hormone receptors. 
The studies described in this thesis revealed that both hMI-ERl ex and hMI-ERl p 
interact with a number of nuclear hormone receptors (ERcx, RARcx, RARP, RAR y, 
RXRcx, and RXRy) in vitro and with ERcx (estrogen receptor alpha) in vivo. Further 
characterization of the in vitro interaction between hMI-ERl and ERcx demonstrated that 
the region important for interaction is located between amino acids 325-357 ofhMI-ERl. 
In vivo studies confirmed the interaction between hMI-ERlcx or hMI-ERlP and 
ERcx in the absence of the ER ligand, estrogen (E2). Interaction in the presence of E2 
appeared to depend on the antibody used for immunoprecipitation. 
Studies into the functional consequences of the interaction show that hMI-ERlP 
enhances estrogen response element (ERE)-driven transcription while hMI-ERlcx has a 
negative, or negligible, effect on ERE-driven transcription. Overall, these results indicate 
that both hMI-ERlcx and hMI-ERl P interact with the estrogen receptor alpha and do 
indeed play a role in the functioning of the estrogen receptor in cells. 
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1. Introduction: 
1.1 genera{ Introduction 
1.1.1 Ce{( Pro(ijeration 
DNA (deoxyribonucleic acid), a molecule found in the nucleus of eukaryotic cells, 
encodes genetic information that determines the structure, function and behaviour of a 
cell. DNA is organized into chromosomes and each chromosome contains a number of 
genes, each of which carry the code for specific proteins. Normal cells have the ability to 
replicate their DNA and produce daughter cells, when necessary. However, alterations or 
mutations in the structure of DNA can occur in a number of ways, including through 
environmental agents such as ultraviolet light, radiation, and genotoxic chemicals, or 
through products of cellular metabolism, such as byproducts of oxidative respiration or 
lipid peroxidation [reviewed in Hoeijmak:er, et al., 2001]. Lesions in the DNA can block 
transcription, the process of copying the information from DNA and producing messenger 
ribonucleic acid (mRNA) for protein production, and interfere with DNA replication. 
The cell's machinery can recognize alterations in the DNA and arrest the cell at specific 
checkpoints in G 1, S, G2 or M phases of the cell cycle in order to allow DNA repair, 
before the cell converts these alterations into permanent mutations [reviewed in Zhou, et 
al., 2000]. A cell can become cancerous through the accunmlation of multiple DNA 
lesions, especially mutations in oncogenes and tumour suppressor genes. Oncogenes are 
genes that, when inappropriately expressed, can release the cell from the normal 
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constraints of cell growth, and change the cell into a cancer cell. Tumour suppressor 
genes code for proteins which negatively regulate the cell cycle, however, inactivation of 
such genes can lead to rapid cell proliferation. 
1.1. 2 rrranscnption 
The transcription of information, into mRNA, contained within a gene is followed 
by a process called translation, where proteins are synthesized according to the mRNA 
sequence. Eukaryotic cells have sophisticated cellular machinery to control and regulate 
the process of gene transcription, including general transcriptional machinery, sequence-
specific transcriptional regulators, mediators and cis-acting regulatory elements within the 
DNA itself. Genes are transcribed by RNA polymerase. RNA polymerase I will 
transcribe genes that encode ribosomal RNA; RNA polymerase II is the central protein 
responsible for mRNA synthesis and RNA polymerase III will transcribe genes that 
encode transfer RNA and small nuclear RNA; RNA polymerase II will assemble with 
general transcription factors, forming what is referred to as basal transcriptional 
machinery, at the promoters of genes (sequences of DNA located upstream of a gene) 
[reviewed in Woychik, et al., 2002]. General transcription factors for RNA polymerase II 
include: TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH, all of which assist with promoter 
melting and unwinding of the DNA. The basal transcriptional machinery also requires 
the presence of sequence or gene-specific transcriptional activators, which specify the 
gene to be transcribed, and a modulator complex, called Mediator, which will transduce 
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regulatory information between gene-specific transcription factors and the core RNA 
polymerase ll machinery [Myers, et al., 2000]. Sequence-specific regulators will bind to 
their corresponding DNA cis-acting regulatory elements, such as TATA box sequences 
and GC boxes, which are part of gene promoters, and to enhancers. The number, 
orientation and location of multiple cis-acting regulatory elements will determine the 
efficiency and specificity of the transcriptional activity of a promoter [Alberts, et al., 
2002]. Enhancers can be located a significant distance from promoters and can function 
in either orientation. The basal transcriptional machinery can also associate with 
sequence-specific transcriptional repressors, rather than activators, which will inhibit 
transcription. 
1.1.3 Chromatin Structure 
DNA found within the nucleus of a cell is wrapped around histone proteins H2A, 
H2B, H3 and H4, each of which is present in duplicate. The octamer ofhistones and the 
DNA wrapped around it is called a nucleosome, and the mass of nucleosomes and DNA 
found in a nucleus is called chromatin. The structure of chromatin helps to condense the 
long sequence of nucleotides into the small space within a cell. Transcription is 
regulated, in part, by this chromatin structure, as DNA in this conformation is only 
partially accessible to transcriptional machinery. Post-translational modification of 
histone proteins through processes such as acetylation and methylation, strongly 
influence the architecture of chromatin. Multi-protein complexes that bind to promoters 
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and enhancers, and that are responsible for communication between activators and 
repressors at sites of transcription initiation, <:rre required to modify this higher-order 
chromatin structure [reviewed in Narlikar, et al., 2002]. Major classes of chromatin-
modifying complexes include: ATP-dependent remodeling complexes, histone acetyl 
transferase (HAT) or histone deacetylase (HDAC) complexes and DNA 
methyltrasferases. 
A. ATP-dependent remodeling complexes: these complexes utilize ATP-hydrolysis to 
increase the accessibility of nucleosomal DNA, a fundamental requirement for 
transcription. ATP-dependent remodeling complexes can be divided into three 
categories, depending on their catalytic ATPase subunit: i)SWI2/SNF2 family, ii) ISWI 
family, and iii) Mi-2 family [Narlikar, et al., 2002]. 
B. HATs and HDACs: Addition of acetyl groups to lysine residues in -terminal regions 
of histone proteins, by an enzyme called HAT, removes the positive charge on the lysine 
residue thereby decreasing the affinity between histone proteins and DNA. The result is a 
destabilization of chromatin structure which causes the chromatin structure to open 
thereby permitting better access of basal transcriptional machinery to the DNA. HDAC 
enzymes remove the acetyl groups from histone proteins thereby stabilizing chromatin 
structure and inhibiting transcription. 
C. DNA methylation: Another fundamental determinant of chromatin structure is DNA 
methylation, the addition of methyl groups to cytosine nucleotides, mediated by enzymes 
called DNA methytransferases [Bestor, et al., 1988] . DNA methylation of cytosine, in the 
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context of CpG dinucleotides, will inactivate genes, while hypomethylation of gene 
promoters will affect DNA-protein interactions and chromatin condensation and allow for 
transcriptional activation [Geimann, et al., 2002; Keshet, et al., 1986; Richardson, 2003]. 
In mammals, patterns of methylation are established early in embryogenesis and are 
stably inherited during normal cell growth [Martienssen, et al., 1995]. Disruption or 
deregulation of this heritable pattern of DNA methylation, such as hypomethylation of 
oncogenes or hypermethylation of CpG islands of tumour suppressor genes, is 
consistently observed early in human cancers [Laird, et al., 1994; Baylin, et al., 1991]. 
1.1. 4 VeveCopment and Cancer 
Both development and cancer are processes involving shifts between cell 
proliferation and differentiation. Research has suggested that deregulation of certain 
developmental genes may result in, or contribute to, oncogenesis. For example, a number 
of cancers, including leukemia, colon, skin, prostate and breast cancers, exhibit 
expression or alterations in homeobox genes [Bijl, et al., 1997; Lawrence, et al., 1996; 
Vider, et al., 1997; Care, et al., 1996; Ford, 1998]. Homeobox genes are regulatory genes 
encoding transcription factors that regulate various aspects of morphogenesis and cell 
differentiation during normal embryonic development [Nunes, et al., 2003]. 
Overexpression ofthe homeobox gene, HSIX1, has been observed in 44% of primary and 
90% of metastatic breast lesions, indicating that HSIX1 may play a role in the progression 
of breast cancer [Ford 1998]. Another example of developmental genes that have been 
linked to cancer are FGFs. These genes play a significant role in gastrulation and 
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organogenesis, particularly with the nervous system, the lungs and limbs [Powers 2000]. 
FGFs are known to stimulate growth, survival and/or differentiation of various 
mesenchyme-derived cells and have also been implicated in malignant tumours [Auguste, 
et al., 2001]. For example, FGF receptor genes, FGFRI and FGFR4, have been found to 
be amplified in 20% and 30% of breast cancer cases, respectively [Dickson, C., et al., 
2000]. 
1.2 :Nucfear Jfonnone CReceptors 
1. 2.1 Structure 
Nuclear hormone receptors are commonly referred to as ligand-inducible 
transcription factors. They include steroid hormone receptors (androgen receptor [AR], 
estrogen receptor [ER], glucocorticoid receptor [GR], progesterone receptor [PRJ, 
mineralocorticoid receptor [MR]) and non-steroid receptors (vitamin D receptor [VDR], 
retinoic acid receptor [RAR], retinoid X receptor [RXR], thyroid hormone receptor [TR]) 
that regulate transcription through vitamin and endocrine signaling. These receptors 
possess the same basic structure (Figure 1) with an NB region at the N-terminus which 
contains an activation function- I (AF-1) domain [steroid receptors] and is responsible for 
ligand-independent transcriptional activation. This region is also involved in protein-
protein interactions. Adjacent to this NB domain is the C region or the DNA binding 
6 
domain (DBD). This is the region of the receptor responsible for recognizing specific 
sequences in the promoters of genes which they regulate, called hormone response 
elements (HREs). C-terminal to the D region, or hinge region, is theE region which 
contains the ligand binding domain (LBD) responsible for ligand-dependent 
transcriptional activation as well as homo/heterodimerization, nuclear translocation and 
interaction with heat shock proteins. This region also contains the activation function 2 
(AF-2) motif. A number of nuclear receptor coregulators interact with the AF-2 region. 
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AlB c D E F 
ERa N- ........ ,-----.---~-----.~.~.--,1-C 
AF-1 AF-2 
D DNA binding domain (DBD) 
D ligand binding domain (LBD) 
0 hinge region 
Figure 1: Domain structure of ERa 
Schematic representation of ERa. The AlB domain, at theN-terminus, is 
responsible for ligand-independent transcriptional activation (AF-1). The 
DNA binding domain (DBD), or C domain, follows and confers the ability 
of the receptor to recognize estrogen response elements (EREs) and thereby 
activate or repress genes. The D domain is the hinge region between the 
DBD and theE domain, or ligand binding domain (LDB). This domain 
contains the AF-2 (activation function 2) motif responsible for ligand-
dependent transcriptional activation. The F domain is a variable region. 
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1. 2. 2 :M.otfe{s for P/1( Punction 
Steroid hormone receptors are responsible for various biological functions 
important during growth, differentiation, inflammation, pregnancy and homeostasis. 
Studies examining the role of the estrogen receptor in such processes has led to the 
realization that it can function through classical (genomic) and non-classical (non-
genomic) methods. 
A. Classical Model: The classical model for nuclear hormone receptor action (Figure 2A) 
begins with ligand binding, which induces conformational changes in the receptor. 
Steroid hormone receptors will form homodimers or heterodimers whereas non-steroid 
receptors will heterodimerize with retinoid X receptor {RXR). Dimers will then undergo 
nuclear translocation where they will next bind directly to HREs, which are target 
sequences located in the regulatory sequences present in the flanking regions of target 
genes. At this point receptors will recruit coactivator complexes to activate transcription. 
If receptors are not bound by agonists or are bound by an antagonist, they will associate 
with corepressor complexes, whose members usually possess HDAC activity, in order to 
inhibit transcriptional activation. 
Nuclear hormone receptors require multiple protein-protein interactions in order 
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to mediate transcription. Protein complexes involved in this transcriptional regulation 
include members of the basal transcriptional machinery as well as coactivator or 
corepressor molecules. Coactivators are commonly associated with HAT activity whereas 
corepressors are associated with HDAC activity. 
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Figure 2: Examples of classical (A) and non-classical (B) modes of action of the 
estrogen receptor. 
A. Classical mode of ER action involves binding of the ligand (estradiol: E2), receptor 
dimerization, nuclear translocation, binding to hormone response elements (HREs ), and 
activation of transcription through association with coactivator complexes that include 
coactivators such as CBP/p300 (CREBbinding protein), P/CAF (p300, CBP associated 
protein), and SRC-1 (steroid receptor coactivator 1). 
B.i. NFKB complexes are kept in an inactive state in the cytoplasm by the association of 
inhibitory proteins (IKB). Exposure of cells to inducers, such as IL-l (interleukin-1 ), will 
result in the degradation of the IKB proteins, allowing for the NFKB dimers to move into 
the nucleus where they activate transcription. ER has been found to associate with the c-
rei subunit of the NFKB complex, which prevents the complex from binding to, and 
activating, the appropriate genes. 
B.ii. ERs have been found to enhance Spl-DNA association, and thereby enhance 
transcription. 
B.iii. FOS and JUN proteins are transcription factors that will heterodimerize and form 
complexes that regulate transcription by associating with API sites in the promoters of 
certain genes. ER will associate with FOS/JUN proteins and ultimately enhance 
transcription. 
[adapted from Nilsson, et al., 2001, and Robyr, et al., 2000] 
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B. Non-classical Models ofER Action: 
ERs have also been found to have non-genomic effects, which are often immediate and 
transient, via signaling pathways more commonly associated with growth factors of cell 
surface receptors. ERs can also regulate transcription through response sites that bind 
transcription factors including Rel!NFKB, Spl, and API, likely through protein-protein 
interactions since ER does not bind to these sites directly [Nilsson, et al., 2001]. Ligand-
independent activation of the ER can also occur through posttranslational modifications, 
such as phosphorylation and acetylation, as well as through interaction with cyclin D 1. 
i) Rel!NFKB is a family of transcriptional regulators, whose activity is controlled by 
subcellular localization. They exist in inactive states in the cytoplasm where they can be 
associated with inhibitory IKB proteins. Treatment of cells with various inducers (such as 
lipopolysaccharides, TNF or IL-l) results in degradation ofthe IKB through 
phosphorylation and ubiquitination. This releases the Rel!NFKB dimer allowing nuclear 
translocation where they can activate appropriate genes. ERa interacts with the c-rel 
subunit of the NFKB complex. This interaction prevents NFKB from binding to and 
stimulating expression from the interleukin-6 (IL-6) promoter (Figure 2B). Therefore, ER 
can inhibit expression of the cytokine IL-6 through a protein-protein interaction [Galien, 
1997]. 
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ii) Both ERa and p physically interact with the Sp1 transcription factor to enhance Sp1-
DNA binding (Figure 2C). For example, both ERa and P can activate transcription of the 
RARa1 gene by the formation ofER-Sp1 complexes on the Sp1 sites ofthe RAR1 
promoter [Sun, et al., 1998; Zou, et al., 1999]. Estradiol (E2) also induces c-fos 
protooncogene expression in MCF-7 cells, which is dependent on the formation of a 
transcriptionally active ER/Sp1 complex [Duan, et al., 1998]. 
iii) ERa and P also interact with the FOS/JUN proteins of the AP1 complex (Figure 2D). 
E2 bound ERa enhances AP1 activity by interacting with the p160 family of coactivators 
whereas ERP bound to anti-estrogens, such as tamoxifen, enhances AP1 activity by 
sequestering corepressors away from the API transcriptional complex [Philips, et al., 
1993; Webb, 1999; Peach, et al., 1997]. In the absence ofE2, ER can also be activated 
by phosphorylation and thereby enhance transcription through AP 1 sites. 
iv) Overexpression of epidermal growth factor receptors (ErbB2 or HER2) has been 
identified in a number of cancer cells. Overexpression of these receptors can activate a 
number of signal transduction pathways in the cell, including MAP kinase (MAPK). 
MAPK hyperactivity has been shown to phosphorylate serine-118 in ERa, resulting in 
ligand-independent receptor activation [Bunone, et al., 1996; Kato, et al., 1995]. 
Overexpression ofHER2 can also induce MTA1 expression. MTAl decreases estrogen 
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response element (ERE)-driven transcription by interacting with ER and allowing for the 
development ofE2-independent growth [Mazumdar, et al., 2000]. 
v) Direct acetylation of the hinge region of ERa by p300 has been shown to regulate 
transactivation and to suppress ligand sensitivity ofthe ER [Wang, et al., 2001]. TAF-IP 
(template-activating factor-IP) will interact with the DNA-binding domain and C-
terrninus of ERa and represses p300-mediated acetylation ofhistone proteins and of ERa, 
decreasing ERa-mediated transcription [Loven, et al., 2003]. 
vi) Cyclin D1, which is overexpressed in a significant number of human cancers, is able 
to act as a bridging factor between unliganded ER and SRC-1 (steroid receptor 
coactivator 1) and thereby recruit coactivators with HAT activity to ER in the absence of 
ligand [Zwijsen, et al., 1998]. For example, Cyclin D1 can trigger activation ofER by 
interacting with a protein containing HAT activity, P/CAF (p300/CREB-binding protein-
associated protein), and thus facilitate the interaction between ER and P/CAF [McMahon, 
et al., 1999]. This interaction can stimulate the transcriptional function of ERin the 
absence of its ligand, estrogen (E2). 
1.3 :Nucfear Jformone ~eceptors ana Cancer 
Approximately two thirds of breast cancer patients have endocrine-responsive 
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disease, and therefore, countless studies have been undertaken in order to more fully 
examine the role of nuclear hormone receptors in breast cancer and to determine which 
hormone therapies could play a critical role in the management of the disease. Down-
regulation of RAR~ and overexpression of RXR have both been associated with 
progression of carcinogenesis in breast cancer [Xu, et al., 1997; Lawrence, et al., 1998]. 
ERa mRNA was shown to be up-regulated during carcinogenesis of breast tumours 
[Iwao, et al., 2000] while ER~ expression was shown to be down-regulated in 
proliferative preinvasive mammary tumours [Roger, et a1.,2001]. 
Both estrogens and progestins effect cell growth and/or differentiation in 
mammary epithelial cells [Vienonen, et al., 2003]. Through interaction with the ER, 
estrogen (E2) can control cell growth and differentiation in normal tissues and in 
hormone-responsive tumours by inducing expression of both immediate early genes as 
well as hormone responsive genes important for cell growth [Perillo, et al., 2000]. For 
example, estrogens have been found to increase expression of PR in breast cancer cells 
[Nardulli, 1988] and to induce both c-Myc and cyclin D1, the induction of either is 
sufficient to affect cell cycle progression. Overexpression of cyclin D 1 has been found in 
many breast cancers [Zwijsen, 1998] and activation of either c-Myc or cyclin D1 will lead 
to early activation of cyclin E-Cdk:2, phosphorylation of pRB and release of E2F. This 
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signaling cascade will ultimately result in DNA synthesis, and cell cycle progression from 
G 1 to S phase [Doisneau-Sioux, et al., 2003]. E2 has also been found to increase RAR 
mRNA levels in breast cancer cells [Roman, et al., 1993] as well as bcl-2 transcription in 
MCF-7 cells [Perillo, et al., 2000]. Other target genes for ERa in hormone-responsive 
breast tumours have been identified, including: pS2, TGF-a, cathepsin D, and GREB1 
[Schurr, et al., 2001; Masiakowski, et al., 1982; Bates, et al., 1988; Cavailles, et al., 1991; 
Ghosh, et al., 2000]. 
Overexpression or hyperactivation of the ER can, thus, drive cells though the cell 
cycle, lead to the activation of numerous genes and ultimately enhance growth and 
progression of breast cancers. This has lead to a great deal of interest in the exploration of 
ways to functionally inactivate ER by suppressing ER-mediated gene-transcription and 
cell proliferation. These approaches have involved the use of anti-estrogens, dominant-
negative ERs and corepressors. 
Eventually, many breast cancers will develop hormone-independence and 
simultaneous amplification of growth factor receptors which results in the development 
of a more invasive and aggressive cancer. Hormone independence can also arise due to 
loss ofER expression by tumours (rare), mutations in ER, alterations in the binding of 
anti-estrogens in breast cancer cells or abnormal interactions between ER and 
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coregulators. ER can interact with corepressors such as SMRT and NCoR in the presence 
of antagonists such as tamoxifen and RU486, however, these become agonists when the 
ligand-independent activation function (AF-1) of the ER is activated by the MAPK 
pathway. This will result in the release of corepressors and recruitment of coactivators 
[Lavinsky, et al., 1998]. This pathway may be one explanation for the development of 
tamoxifen-resistance in some breast cancer patients. 
Gene amplification and overexpression of a number of ER coactivators such as 
SRC-3, AIB3, TRAP220 have been identified in breast and ovarian cancer [Anzick, et al. , 
1997; Lee, et al., 1999; Zhu, et al., 1999]. Changes in expression patterns of corepressors 
or the ratio between coactivators and corepressors in breast cancer cells may contribute to 
the development of chemotherapy-resistance in breast cancer treatment [Lavinski, et al., 
1998]. The expression of hmi-erl (see below) was found to be negligible in fifty normal 
human tissues tested, however, hmi-er 1 was consistently expressed in nine breast 
carcinoma-derived cell lines and eight breast tumour tissues samples tested, indicating 
that hMI-ER1 may indeed be associated with human breast carcinoma [Paterno, et al., 
1998]. At present, a definitive link between cofactor levels or activity and cancer has yet 
to be established, however, evidence does point toward a relationship between cofactors 
and carcinogenesis. Therefore, a clearer understanding of the mechanism of action of 
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estrogen, as well as cross-talk with other signal transduction pathways, is crucial for the 
development of more effective breast cancer therapies. 
1.4 li!MI-P.<Rl 
1.4.1 :MIP/Rc 1 Structure 
A number of years ago, investigations into the role of fibroblast growth factor 
(FGF) in cell growth and differentiation in Xenopus laevis embryos led to the 
identification of a novel immediate-early gene, or initial target, of FGF signal 
transduction, which was later named mesoderm induction early response 1 (mi-er 1) 
[Paterno, et al., 1997]. FGF increased expression levels of Xenopus mi-er 1 (xmi-er 1) in 
embryo explants during mesoderm induction [Paterno, et al., 1997]. During early embryo 
development, xmi-er 1 mRNA levels are evenly expressed during early cleavage (stages 2, 
6, and 7), slightly increased at blastula stage and decreased by 6-fold during gastrula, 
neurula and tailbud stages (stages 12, 17 and 22), and undetectable in subsequent 
developmental stages [Paterno, et al., 1997]. 
A human orthologue of xmi-er 1, hmi-er 1, was also cloned in our laboratory 
[Paterno, et al., 1998; Paterno, et al., 2002]. A number of studies have since been 
conducted in order to characterize its structure and function. hmi-er 1 is a single copy, 63 
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kilobase gene, that ultimately gives rise to 6 protein isoforms with a common internal 
region and varying- (Nl, N2, and N3) and C-termini (ex and p): Nlcx (457 aa), NIP (536 
aa), N2cx (432 aa), N2P (511 aa), N3cx (433 aa) and N3P (512 aa) (Figure 3). hmi-erl 
consists of 1 7 exons, with exons 4 to 15 encoding the sequence for the common internal 
region, exon 3A acting as a skipped ex on which gives rise to one of the alternate 
N- termini (Nl), and intron 15 functioning as a facultative intron and giving rise to one of 
two alternate C-termini (ex and p). Close analysis ofthe hMI-ERlP-isoform and XMI-
ERl proteins revealed that they display 91% sequence similarity [Paterno, et al., 1998]. 
Two alternate promoters were identified for hmi-er 1. Use of the first promoter, 
and inclusion of exon 3A, will result in an ML- amino acid N- terminal sequence and a 25 
amino acid insert (Nl) whereas use of the first promoter alone results in an ML- amino 
acid N-terminal sequence (N2). The second promoter gives rise to an MAE- N-terminal 
amino acid sequence (N3). Two distinct C-termini arise due to alternate use ofthe 
facultative intron 15. The a C-terminus arises from removal ofthe intron to result in a 
rarer, 23 amino acid, sequence whereas the P C-terminus, which arises from inclusion of 
intron 15, encompasses 102 amino acids. Different amino acid sequences for a and p 
termini suggest alternate functions. 
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Figure 3: Structure of hMI-ERl 
A. The amino acid sequences of the three alternate N-termini are shown. The 
first promoter and inclusion of exon 3A will give rise to an ML- amino acid 
start sequence (N1), however, the first promoter alone will result in an ML-
amino acid N- terminal sequence (N2). The second promoter gives rise to an 
MAE- N- terminal amino acid sequence (N3). 
B. Schematic illustrating two isoforms ofhMI-ER1: N3a (433 aa) and N3~ 
(512 aa). Each of the six protein isoforms contain the common internal 
region (410 aa) that includes the acidic activation domain, ELM-2 and SANT 
domains as well as one of two alternate C-termini and one of three alternate 
N-termini: N1a (457 aa), N1~ (536 aa), N2a (432 aa), N2~ (511 aa), N3a 
(433 aa) and N3~ (512 aa). The number of amino acids present in each 
isoform is indicated in brackets on the left. 
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1. 4. 2 Punctiona{ (J>rotein :Motifs 
Studies examining the role of xmi-er 1 in embryonic development gave the first 
indications as to possible functions for this novel gene in vivo. Recently, a study found 
that overexpression of xmi-er 1 in Xenopus laevis embryos lead to truncations of the 
anterioposterior axis and dramatically reduced the percentage of explants induced to form 
mesoderm by FGF-2 [Teplitsky, et al., 2003]. Whole mount in situ hybridization assays 
for brachyury (Xbra), an early mesodermal marker, also demonstrated a significant 
reduction of Xbra expression in xmi-er 1 injected embryos. This study indicates that XMI-
ERl negatively regulates FGF, thereby limiting mesoderm induction in vivo [Teplitsky, et 
al., 2003]. 
Close examination of the protein structure of both XMI-ERl and hMI-ERl, and 
comparison to other known proteins, led to the identification of a number of putative 
functional protein motifs, each of which provide indications as to possible function of this 
novel protein. 
A. ELM2 Domain: This domain derives its name from EGL-27 and MTAl homology 2. 
It is a domain commonly found in proteins, such as XMI-ERl and in the common region 
ofhMI-ERl, with roles in transcriptional regulation, a number of which also include a 
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SANT domain. The ELM2 domain was recently found to recruit histone deacetylase 1 
(HDACl) activity to hMI-ERl [Ding, et al., 2003]. HDACs catalyze the removal of 
acetyl groups from histone proteins, resulting in closing of the chromatin structure and 
repression of transcription. In order to examine the role of hMI-ERl a and hMI-ERl P in 
transcription HeLa cells were transfected with a reporter plasmid, G5tkCAT [containing 
CAT (chloramphenicol acetyltransferase) and five Gal4 DNA binding sites], and either 
GAL4DBD, GAL4DBD-MIER1a, or GAL4DBD-MIER1P constructs. GAL4DBD is a 
pM plasmid containing a nuclear localization signal (NLS) and the GAL4 DNA binding 
domain alone or fused to hmi-er 1 a or hmi-er 1 fJ. Cell extracts from cells transfected with 
G5tkCAT and GAL4DBD will display a basal level CAT expression, which is a measure 
of transcriptional a~tivation. If hlvP-ER 1 !X o.r 4MI-ERl P affect transcription, the level of 
CAT expression would either be increased or decreased in cells transfected with 
G5tkCAT and GAL4DBD-MIER1a or GAL4DBD-MIER1p. This study found that both 
hMI-ERla and hMI-ERlP physically associate with a functional HDACl protein in vivo, 
and repress transcription of the G5tkCA T reporter plasmid in a dose dependent manner 
[Ding, et al. , 2003], indicating that hMI-ERl has a definite role in the regulation of 
transcription. 
B. SANT Domain: A single SANT domain was identified in the common region ofhMI-
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ERl, downstream of the ELM2 domain. This domain, which is similar to the DNA-
binding domain ofMyb-related proteins, was identified in transcription factors SWI3, 
ADA2, NCoR and TFIIIB, for which the SANT domain was named [Aasland, 1996]. 
Proteins with one or more copies of the SANT domain are also commonly involved in 
protein-protein interactions including those involved in regulating nuclear hormone 
activity (ex: NCoR, SMRT), chromatin remodeling (ex: MTA-1 and MTA-2) and 
developmental events (Egl-27, CoREST) [You, 2001]. SANT domains can be found in 
proteins in HAT and HDAC complexes. SANT containing proteins, SMRT (silencing 
mediator for retinoid and thyroid receptors) and NCoR (nuclear receptor co-repressor) 
interact with multiple HDACs and mediate repression for a number of transcription 
factors, including unliganded nuclear hormone receptors. TheN- terminal SANT domain 
(SANTI) ofboth SMRT and NCoR interact with, and activate, HDAC3 via a deacetylase 
activation domain (DAD) [Guenther, 2001]. The second SANT domain (SANT2) of 
SMRT, located within a histone-interaction domain (HID), inhibits acetylation of histone 
proteins by HATs [Yu, 2003]. The SANT domain of Ada-2, however, is essential for 
HAT activity ofGcn5p-containing HAT complexes [Boyer, 2002)]. 
C. LXXLL motif (or NR-box): This motif, where L represents leucine and X can 
represent any amino acid, was identified in the ex C-terminus ofhMI-ERl and is 
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commonly found in nuclear hormone receptor coactivators (SRC-1, CBP, MICoA) and 
corepressors (NCoR, SMRT, DAX-1, RIP140, LCoR) [Heery, et al., 1997]. The LXXLL 
domain ofMICoA (MTA1-interacting coactivator), for example, will bind to the AF-2 
(activation function-2) motif in the estrogen receptor (ER). Interaction between MICoA 
and ER will stimulate ER-transactivation function in one of two ways: MICoA will act as 
a coactivator itself, associating withER and its estrogen response element (ERE), or 
interact with other coactivators [Mishra, et al., 2003]. MTA1 can bind to the LXXLL 
motif in MICoA to repress MICoA-mediated stimulation of ERE-driven transcription 
[Mishra, et al., 2003]. The LXXLL domain of MICoA is responsible for its interaction 
withER and MTA1 and the transactivation function ofMICoA, as well as for its 
movement to the nucleus [Mishra, et al., 2003]. 
Both DAX-1 and RIP140 (receptor interacting protein 140) inhibit transcriptional 
activation of a number of nuclear hormone receptors. DAX -1 inhibits the transcriptional 
activation of liganded ERa and ER~ by binding directly to the receptors via anN -
terminal repeat domain, containing multiple LXXLL motifs [Zhang, et al., 2000]. The 
single LXXLL motif ofLCoR (ligand-dependent corepressor) is responsible for 
recruitment ofLCoR to agonist-bound nuclear receptors [Fernandes, et al., 2003]. 
Some LXXLL-containing proteins have both coactivator and corepressor function, 
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such as CIA (coactivator independent of AF-2 function) [Sauve, et al., 2001]). Other 
LXXLL-containing proteins will interact with nuclear hormone receptors and affect their 
function, but will not interact through this motif. REA (repressor of estrogen activity), 
for example, will bind to ligand-boundER and suppressER-activated gene transcription, 
however, the LXXLL motif in REA is not required for interaction with ER [Martini, et 
al., 2003]. 
An 8-amino acid sequence spanning from position -2 to +6, relative to the first 
leucine residue of the LXXLL motif, influences the affinity and selectivity of coregulators 
for nuclear hormone receptors. A hydrophobic residue at position -1 and a 
nonhydrophobic residue at +2 conveys high affinity ofthese proteins for steroid and 
retinoid receptors [Heery, et al., 2001]. This is indeed the case with hMI-ER1a., with a 
hydrophobic isoleucine at position -1 and a hydrophilic glutamine at position +2. 
D. Acidic Activation Domain: There is much evidence to support a role for acidic 
activation domains, areas rich in acidic amino acid residues, in the recruitment of 
transcriptional machinery by protein-protein interactions [Melcher, 2000]. Four regions 
rich in acidic amino acid residues have been identified in the common, - terminal region 
ofhMI-ERl. Transient transfection assays were completed with NIH 3T3 cells using 
constructs containing various regions of xmi-er 1 fused to the GAL4DNA binding domain 
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and a CAT reporter plasmid [Paterno, et al., 1997]. The first 98 amino acids of the 
N- terminus ofXMI-ER1 stimulated transcription 80-fold whereas full length XMI-ER1 
did not activate transcription, indicating that the -terminus ofXMI-ER1 contains a 
transcriptional activation domain [Paterno, et al., 1997]. XMI-ER1 could, therefore, 
function as a transcriptional activator. 
E. Proline Rich Motif: SH3 domains are small protein motifs, of about 60 amino acids in 
length, commonly found in signaling proteins and enzymes which recognize proline-rich 
motifs as their interacting partners [Vidal, et al., 2001]. A proline rich motif (PXXP; P 
represents proline, X represents any amino acid motif) was identified in the common 
region ofhMI-ERl and in XMI-ER1, located C-terminal to the SANT domain. Studies 
investigating the importance of a number of functional domains ofXMI-ERl 
demonstrated that proline 365, within the proline rich motif, mediates the activity of 
XMI-ER1 in Xenopus embryo development, ultimately affecting the extent of mesoderm 
formation during embryonic development [Teplitsky, et al., 2003]. 
1.4.3 Su6ce{{ufar LocaEization of li:Jvtl-P/R.) 
Immunohistochemical studies of Xenopus laevis embryos during various stages of 
development revealed that XMI-ER1 is found exclusively in the cytoplasm during early 
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developmental stages but progressively accumulates in the nuclei of marginal zone cells 
of stage 8 blastulae, and is located exclusively in nuclei in the animal hemisphere by late 
blastula stage (stage 9) [Luchman, et al., 1999]. Transfection assays with NIH 3T3 cells 
revealed that XMI-ER1 translocated exclusively to the nuclei [Paterno, et al., 1997]. Four 
putative nuclear localization signals (NLS; NLS1, NLS2, NLS3 and NLS4) were 
identified in XMI-ER1, however, there is only one functional NLS (NLS4) located in the 
C-terminal domain [Post, et al., 2001]. Further analysis ofhMI-ER1a. and P revealed 
that hMI-ERl p is targeted exclusively to the nucleus whereas hMI-ER1 a. remained 
cytoplasmic [Paterno, et al., 2002]. These results were expected as hMI-ER1a. has no 
functional NLS, however, they do not rule out the possibility that hMI-ERla. could be 
transported into the nucleus through interaction with other proteins, such as HDAC or 
nuclear hormone receptors. 
1.5 Cl'urpose oftliis Stuay The presence of an acidic activation domain, ELM2 and 
SANT domains as well as proline rich motif, indicates that hMI-ER1 is likely involved in 
protein-protein interactions and an LXXLL motif in hMI-ER1a. indicates that this protein 
likely interacts with nuclear hormone receptors. Evidence also indicates that hMI-ERl 
plays a role in the regulation of transcription. The purpose of this study was to determine 
ifhMI-ER1a. interacts with nuclear hormone receptors, through the LXXLL motif, and 
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thereby affect the functioning of nuclear receptors as transcription factors. 
Objective 1: Identification ofhMI-ERJ interacting nuclear hormone receptors. A 
number ofGST-pull down assays were completed with GST-hMI-ERla or GST-bMI-
ERlP and in vitro translated 35S-labeled nuclear hormone receptors in order to obtain 
preliminary evidence of an interaction between the receptor(s) and bMI-ERl. 
Objective 2: Identification of the region ofhMI-ERJ responsible for interaction with 
ERa. Previous data indicated that bMI-ERllevels were increased in breast tumour cells 
and tissues [Paterno, et al., 1998], therefore, further studies focused on characterizing the 
interaction between bMI-ERl and ERa, a nuclear hormone receptor with significant 
implications in breast cancer. GST-bMI-ERl deletion constructs were used in a number 
of GST -pull down assays in order to determine the region ofhMI-ERl responsible for 
interaction with ERa. 
Objective 3: Characterization of the in vivo interaction between hMI-ERJ and ERa. A 
human estrogen receptor positive breast carcinoma cell line (MCF-7) and a human 
embryonic kidney cell line (HEK 293) were used for assays which helped to further 
characterize the interaction ofbMI-ERl and ERa within cells. 
Objective 4: Characterization of the role ofhMI-ERJ in ERE-driven transcription. The 
recruitment ofHDACl activity to bMI-ERl through the ELM2 domain indicates that 
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bMI-ERl is involved transcriptional regulation. Assays were therefore completed to 
determine if the interaction between ERa and hMI-ERl would influence ERE-driven 
transcription. 
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2. Materials and Methods: 
2.1 CFfasmidS am£ Constructs 
A.CS3MT, CS3MT-hmi-er1 cx!p 
Expression vectors were engineered, by z. Ding in our laboratory, to contain full 
length hmi-er1cx or hmi-er1P fused to the Myc epitope tag ofCS3+MT plasmid 
(gift from David Turner, University of Michigan). The entire coding sequence of 
either hMI-ER1cx or hMI-ER1P [accession numbers AY124187 and AF515447, 
respectively] was amplified by PCR with the use of specific primers incorporating 
5' and 3' BamHI sites (Table 1). The PCR fragments were inserted into the Bgill 
site of the CS3+MT plasmid [Ding, et al., 2003]. PCR primers used for preparing 
hmi-er 1 constructs are listed in Table 1. 
B. GST -hmi-er 1 cx!p 
GST -hmi-er 1 fusion constructs were produced by Z. Ding, obtained by subcloning 
the appropriate eDNA isoform into the pGEX-4T-1 vector (Pharmacia, Biotech). 
A number ofhMI-ER1 deletion mutants were generated by amplifying fragments 
encoding the appropriate amino acid residues ofhMI-ERl cx/p, using the primer 
pairs listed in Table 2. PCR products were cloned into pCR3.1 and EcoRI 
fragments were then inserted into the complementary sites ofthe pGEX-4T-l 
plasmid. 
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C. pcDNA3-ERa 
The pcDNA3 vector, containing the complete coding sequence of estrogen 
receptor ex [accession number NM_000125], was a kind gift from Dr.Christine 
Pratt, University of Ottawa. A partial nucleotide sequence was determined and the 
remaining sequence was determined by Toronto's Hospital for Sick Children, 
DNA Sequencing Facility. 
D.RARs,RXRs 
pCMX-hRARcx, pRC/RSV-hRAR~, pGEM-mRARy, pSG5-mRXRcx, and pSG5-
mRXR y, were kind gifts from Dr. Christine Pratt, University of Ottawa 
[accession numbers NM_000964, NM_000965, M34475, M84817, and M84819, 
respectively]. Partial sequences were determined in order to verify clones 
received. 
E. pS2, ~pS2, vERETKLuc 
pS2-ERELuc, pS2~ERELuc, and vERE(3) TKLuc were kind gifts from Dr. 
Vincent Giguere, McGill University. 
pS2-ERELuc contains ~ 1050 bp pS2 promoter [Berry, et al., 1989] preceding the 
luciferase reporter ofpGL3 (Promega)[Tremblay, et al., 1997]. In the 
pS2~ERELuc construct, the ERE sequence was replaced by sequences encoding 
EcoRI-EcoRV sites, generated by PCR mutagenesis using the ExSite kit from 
Stratagene as described by the manufacturer [Tremblay, et al., 1997]. 
vERE(3) TKLuc was constructed by ligating three copies of the vitA2-ERE 
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oligonucleotide (5'-TCGACAAAGTCAGGTCACAG-TGACCTGATCAAG-3') 
into Sall-BamHI-digested TKLuc vector [Tremblay, et al., 1997]. 
;E. pGL3-Basic and pGL3-Control 
Control vectors were obtained from Promega Corporation. pGL3-Basic lacks 
eukaryotic promoter and enhancer sequences whereas pGL3-Control vector 
contains SV 40 promoter and enhancer sequences allowing for strong expression 
of luciferase in many mammalian cell types. 
2.2 In vitro fJ'ranscription-fJ'ransfation antfriCA Cfrecipitation 
.,.. Coupled transcription-translation reactions (TNT; Promega) were performed as per 
manufacturer's instructions. Briefly, 10 j.!l DEPC water and the following reaction 
components, provided by the manufacturer, were assembled in a 1.5ml centrifuge tube: 2 
j.!l TNT reaction buffer, 25 j.!l reticulocyte lysate, 1 j.!l T7 /SP6/T3 polymerase, 1 j.!l amino 
acid mixture (minus met~onine). 1 j.!l of ribonuclease inhibitor (RNA Guard (27-0815-
0 1 ); Amersham Biosciences) and 5 j.!l [35S] methionine were then added to the master mix 
and fmally, 1 J..Lg of plasmid DNA template was added to the master mix. Reactions were 
incubated for 90 minutes at 30 °C . 
.,.. TCA (tricholoroacetic acid) precipitation assays were conducted in order to determine 
the efficiency of the in vitro transcription/translation reaction. Briefly, 98 j.!l of a 1N 
NaOH/2%H
2
0
2 
solution was mixed with 2 j.!l of the TNT. The reaction was incubated at 
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3 7 °C for 1 0 minutes. 900 Jll of ice cold 25% TCA/2% casein amino acid solution was 
then added and the reactions were incubated for 30 minutes on ice. Precipitate was then 
collected on Fisher filter paper and counted in a Beckman S3801 Spectrophotometer. 
2. 3 (]Sfl' (]Ju{[ Vown Assays 
2.3.1 qCutatliione Sepliarose 4CB CBeadS 
Glutathione Sepharose 4B beads (Pharmacia Biotech) were prepared as per 
manufacturer's instructions. Briefly, beads were gently resuspended by shaking. 1.33ml 
of the 75% slurry was placed into a 15ml falcon tube. The beads were centrifuged at 500 
x g for 5 minutes. Supernatant was removed and 10 ml of ice cold 1X PBS was added to 
the tube. GST beads and PBS were then mixed by inversion. The beads were centrifuged 
again at 500 x g for 5 minutes. Supernatant was removed and 1 ml of 1X PBS was added 
to result in a 50 % slurry. Beads were kept for up to a month at 4 °C. 
2.3.2 Pusion Protein Proauction 
10 ng of a pGEX-4T1-1plasmid was added to 100 Jll ofBL21Codon Plus RP competent 
E. coli [Strategene]. The reaction mixture was kept on ice for 30 minutes then placed in a 
water bath at 42°C for 45 seconds. 900 Jll of Luria broth (LB) medium [5g peptone, 2.5g 
yeast extract, 5g NaCl, 500mL dH20 ; autoclaved] was added and the culture was shaken 
for 1 hour at 3 7°C. Samples were then quickly centrifuged ( - 1 0 - 20 seconds), after 
which most of the supernatant was removed, leaving approximately 100 Jll. The pellet 
was resuspended in the remaining liquid. Using aseptic technique, all of the resuspended 
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pellet was added to an agar-ampicillin plate. Agar plates were prepared by mixing 5g 
peptone, 2.5g yeast extract, 5g NaCl, and 500mL dH20. The agar solution was 
autoclaved, and when liquid had cooled, ampicillin was added for a final concentration of 
50 flg/ml. This solution was poured into petri dishes (enough to cover the bottom of 
plate). The agar-ampicillin plate was inverted and incubated overnight at 37 °C. The next 
morning, the plate was placed into a refrigerator at 4 °C. In the afternoon, 5ml LB 
medium, with 50flg/ml ampicillin, was inoculated with one colony from the agar-
ampicillin plate. This culture was shaken overnight at 3 7 °C. The next morning, 250 ml 
LB medium, with 50 flg/ml ampicillin, was inoculated with 2ml of the overnight culture 
and shaken at 37 °C. After approximately 2.5- 3 hours, the OD of the culture was 
verified. Briefly, lml ofLB medium was added to one cuvette for calibration and lml of 
the inoculated culture was added to another cuvette. OD was read in a spectrophotometer 
at a wavelength of 595nm. The inoculated cultur~ was grpwn until the OD reading was 
between 0.6 - 0.8. At that point, 25 fll of 1M IPTG (isopropyl-P-D-
thiogalactopyranoside) was added to the culture, which was subsequently shaken at 3 7 °C 
for another 3 hours. The inoculated culture was poured into a 250ml Nalgene 
polypropylene bottle and centrifuged in a Sorval centrifuge at 4000 rpm for 10 minutes. 
All the liquid was drained off and the pelleted cells were resuspend in 5ml of ice cold lX 
PBS. The resuspended pellet was placed into a new falcon tube where 25 fll of 0.2M 
PMSF and 50 fll100x protease inhibitor (PI) [10 mg aprotinin, 10 mg leupeptin, 50 mg 
nor-P-Tosyl-L-Lysine Chloromethyl Ketone, 10 ml water] was added. Cells were then 
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lysed by 1 minute of mild sonication. At this point, 500 )ll of 10% Triton X-100 was 
added to the tube which was then centrifuged at 16,000 x g for 15 - 20 minutes. The 
soluble fraction (supernatant) was removed and placed into a new tube and stored at -70 
°C. GST fusion protein level and purity were determined by SDS-PAGE. 
2.3.3 qsr pu{{ down assays 
ERa, RARa, RAR~, RARy, RXRa, or RXRy were labeled with [35S] methionine 
through in vitro transcription/-translation reactions. 
For each GST pull down reaction, 50 )ll of a 50% slurry of GST -Sepharose beads were 
washed two times with GST buffer [20mM Tris-Cl pH 7.5, 150 mM NaCl, 1 mM EDTA, 
10% glycerol, 0.5% NP40, 1x PI (protease inhibitor), 0.2% bovine serum albumin 
(BSA)]. Beads were then resuspended in GST buffer (minus BSA) and rotated at 4 oc for 
1 hour with indicated GST-hMI-ER1 fusion protein. GST-bound beads were subsequently 
washed five times with 500 )ll of GST buffer, resuspended in GST buffer (minus BSA) 
and rotated 2 hours with [35S] methionine-labeled in vitro translated ER a, RARa, RAR~, 
RARy, RXRa, or RXRy (100,000 cpm) at 
4 °C. Beads were then washed three times with 500 )ll of GST buffer (minus BSA), 
twice with 500 )ll of GST buffer (minus BSA and NP40) and, finally, twice with 500)ll of 
150 mM NaCl. Beads were resuspended in 30 )ll of2x SDS loading buffer [5ml 0.5 M 
Tris pH 6.8, 5 ml 20% SDS, 2.5ml ~-mercaptoethanol, 5ml glycerol, 5ml dH20], boiled 4 
minutes and loaded on 8% SDS-polyacrylamide gel. Samples were analyzed by 
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autoradiography. Input lanes contained 1/10 volume of the indicated 1NT used for each 
reaction . 
... For serial dilutions (Figures 4- 9), 0.25 J.!g, 0.5 Jlg, 1 J..lg or 2 !lg ofGST-MIER1~ 
fusion protein was used for the pull down assays, as indicated . 
... For GST-pull down assays completed with retinoic acid (RA) [ligand for RAR a and 
RAR~] or 17~-estradiol (E2) [ligand for ERaJ1J.!g ofGST-MIER1a or GST-MIER1P 
were used in each pull down assay [Figures 10- 12]. 0.5J.Ll of 1 mM RA or lj.Ll of 5 mM 
E2, or an equal volume of vehicle (DMSO or ethanol, respectively), was added directly to 
the GST buffer in order to obtain a fmal concentration of 1 o-6 M. After GST beads and 
GST-MIER1 fusion proteins were incubated together for one hour (as described above), 
beads were resuspended in GST -buffer with added ligand [without BSA] and fmally 
100,000 cpm of [35S] methionine-labeled in vitro translated ERa, RARa, or RARP was 
added to the reaction . 
... For GST-pull down assays completed with pre-incubation ofligand and receptor 
[Figure 13], 
1j.Ll of 5 mM E2 (fmal concentration of 1o-6 M E2), or an equal volume of ethanol 
(vehicle), was pre-incubated for 15 minutes with e5S] methionine-labeled in vitro 
translated ERa [100,000 cpm] and GST buffer [without BSA] before being added to the 
GST-bound beads . 
... GST-pull down assays with various GST-hMI-ERl deletion constructs [Figures 15 and 
16] were completed with 0.1 pmoles ofGST-MI-ERla, GST-MI-ER1p, GST-~4, GST-
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~5, GST-~9, GST-~10, GST-~11, GST-~13, GST-~16, GST-~17, GST-~18, or GST-
~19 in 500!-!1. 
2.4 Ce{[ Culture 
Human cell lines, MCF-7 (human breast carcinoma) and HEK 293 (transformed human 
embryonic kidney), were obtained from the American Tissue Culture Collection. MCF-7 
cells were cultured at 10% C02 and 293 cells were cultured at 5% C02 in Dulbecco's 
modified Eagle's medium (DMEM)[Hyclone] containing 10% fetal calf serum (FCS) 
[Invitrogen]. 
2.5 fJ'ransfections: :M.CP-7 Ce{[s 
3.0 x 105 cells/well ofMCF-7 cells were seeded in 6-well plates 18 h prior to transfection 
in phenol red free (PRF) DMEM with 10% charcoal stripped FCS (HyClone). All 
transfections were performed in duplicate in 6-well plates with 4 1-11 Lipofectamine Plus 
per well, according to the manufacturer's instructions (Life Technologies, Inc.), with the 
indicated amounts of DNA. Complexes were left on cells for 4 hours after transfection at 
which point medium with lipofectamine was aspirated from the cells and 2ml of fresh 
PRF DMEM was added to each well. Cells were grown in PRF DMEM with charcoal 
stripped FCS, for approximately 48 hours after transfection and exposed to either 1o-9 M 
17~-estradiol (E2) [Sigma], or an equal volume of ethanol (vehicle), for 6 hours prior to 
harvesting. 10·9 M is considered to be an E2-saturating condition for MCF-7 cells but also 
a physiologically relevant concentration, with the physiological range of E2 between 1 o-12 
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to 10-9 M [Hayashi, et al., 2003]. 
For in vivo immunoprecipitation (IP) assays with MCF-7 cells, cells were transfected 
with 1 J..lg of pCS3+MT, pCS3+MT -hmi-er 1 a, or pCS3+MT -hmi-er 1 P per well of a 6-
well plate. 48 hours after transfection, and after a 6 hour incubation with 1o-9 M E2 or an 
equivalent volume of ethanol, each well was washed with 2ml 1X PBS. In order to 
consolidate two wells for one IP, a 500 J.!l of a 1X Triton Solution [10 ml1M Tris, pH 
7.5, 10m1100% Triton, 20 ml 0.5M EDTA, 1 ml2% sodium-azide and 59 ml dH20; 50 !J.l 
0.2M PMSF and 1 OOj.Ll 1 OOX PI were added to buffer immediately before IP] was added 
to each well. Cells were scraped and plates were placed on ice for 20 minutes. Lysate 
was pulled through a syringe -15 - 20 times and lysate from two wells was transferred to 
one 1.5ml tube. Insoluble material was removed by centrifugation at 16,000 x g, 4 °C, 5 
minutes. Supernatant was removed and placed in a new 1.5ml tube at which point a 1 :25 
dilution of anti-Myc (9E10, Developmental Hybridoma Bank) antibody was added for IP. 
Tubes were rotated overnight at 4 °C. 
After an overnight rotation, 50 J.!l of a 50% slurry of Protein G beads was then added to 
the tubes and rotated 1 hour at 4 °C. Finally, bound beads were washed three times with 
1X Triton Solution [with PMSF and PI added just before washes], and twice with 150 
mM NaCl. Beads were resuspended in 30 J.!l of2x SDS loading buffer, boiled 4 minutes 
and loaded on 8% SDS-polyacrylamide gel. ERa TNT lanes contained 2J.!l (between 
100,000 to150,000 cpm) of e5S] methionine-labeled in vitro translated ERa and 30 J.!l 
SDS loading buffer. Gels were run for approximately 1.5 hours at 30 rnA in order to 
38 
allow full separation of protein components. SDS gels were shaken and washed three 
times in Transfer buffer [200ml 5X stock buffer (60.54g Tris, 288.4g glycine, 3L dH20), 
200 m1 methanol, 600 ml dH20] for 15 minutes to help remove SDS for efficient protein 
transfer. Proteins were then transferred to a Hybond-ECL nitrocellulose membrane 
(Amersham) for 2 hours at 60 V. The blot was then shaken in 5% skim milk powder/1X 
TBS-T [20mM Tris pH7.6, 137 mM NaCl, 0.1% Tween-20, dH20], at room temperature 
for 2 hours. Western blot analysis for IP samples was performed with a 1:800 dilution 
of a rabbit polyclonal anti-ERa (Santa-Cruz sc-543) antibody in 1X TBS-T. Blots were 
agitated in this solution overnight at 4 °C, washed 4-5 times in 1 hour at room 
temperature in lX TBS-T, and agitated for 1 hour at room temperature in a 1:2500 
dilution of donkey anti-rabbit conjugated to horseradish peroxidase (HRP) secondary 
antibody in 1X TBS-T. Finally, blots were washed 4-5 times in 1 hour, shaking in lX 
TBS-T, at room temperature and analyzed with chemiluminescent detection using ECL 
Western Blotting System and Hyperfilm ECL from Amersham Technologies. 
For Western Blot analysis of pure protein extracts, in order to verify protein expression, 
transfected cells were washed with 2ml1XPBS. Then 200 Ill of2XSDS loading buffer 
was added per well. The plate was placed on ice for 5 minutes then the lysate was pulled 
through a syringe 10 times. The lysate was stored at -20 oc until needed. For loading on 
8% polyacrylamide gel, 35!ll of straight protein lysate was added to a new Eppendorftube 
along with 5 !ll2X SDS loading buffer (plus bromophenol blue dye). Samples were 
boiled and loaded directly on an 8% polyacrylamide gel and run as above. After proteins 
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were run on the SDS gel, the gel was washed 3-4 times, shaking, in 1X transfer buffer for 
15 minutes and then transferred onto a nitrocellulose membrane, as above. The membrane 
was then placed in 5% skim milk powder/1X TBT, shaking at room temperature for 2 
hours. Western blot analysis was performed with a 1: 1000 dilution of a rabbit polyclonal 
anti-ERa. (Santa-Cruz sc-543) antibody in 1X TBS-T or a 1:200 dilution ofanti-Myc 
antibody in 5% skim milk powder/lX TBS-T. Blots were shaken overnight at 4 oc and 
then washed 4-5 times in 1 hour at room temperature in 1X TBS-T. Blots were then 
shaken 1 hour at room temperature in a 1 :2500 dilution of donkey anti-rabbit HRP 
secondary antibody in 1X TBS-Tor 1:3000 dilution of sheep anti-mouse HRP in 5% 
skim milk powder/ IX TBS-T. Finally, blots were washed 4-5 times in 1 hour, shaking in 
1X TBS-T, at room temperature. Samples were analyzed with chemiluminescent 
detection using ECL Western Blotting System and Hyperfilm ECL from Amersham 
Technologies. 
2. 6 r:fransfections: J{P:K 293 Ce[[s 
For in vivo immunoprecipitation (IP) assays with HEK 293 cells, 6.0 x 10 5 cells/well 
HEK 293 cells were seeded in 6-well plates 18 h prior to transfection in phenol red free 
(PRF) DMEM with 10% charcoal stripped FCS (HyClone). Cells were transfected with 
0.4 !lg ofpcDNA3.1- ERa and 0.4 !lg of either pCS3+MT, pCS3+MT-hmi-erla. or 
pCS3+MT-hmi-erl~. All transfections were performed in triplicate in 6-well plates with 
4 Ill Lipofectamine Plus per well, according to the manufacturer' s instructions. 
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Complexes were left on cells for 4 hours after transfection at which point medium with 
lipofectamine was aspirated off of cells and 2ml of fresh PRF DMEM was added to each 
well. Cells were grown in PRF DMEM with charcoal stripped FCS, for approximately 48 
hours after transfection and exposed to either 1o-9 M E2, or an equal volume of ethanol, 
for 6 hours prior to harvesting. Each well was then washed with 2ml lX PBS. In order to 
consolidate three wells for one IP, 333 J.tl of a different lysis buffer [50 mM Tris-HCl, 
pH 8.0, 150 mM NaCl 10% glycerol, 1% Triton, 40 mM sodium pyrophosphate (Na4P 20 7 
·10H20), 50 mMNaF, 1 mM orthovanadate; 1M PMSF and lX PI were added to buffer 
immediately before IP] was used rather than 1 X Triton Solution. Cells were scraped and 
allowed to sit on ice for 20 minutes. Lysate was pulled through a syringe~ 15- 20 times 
and lysate from three wells was transferred to one 1.5ml tube. Insoluble material was 
removed by centrifugation at 16,000 x g, 4 °C, 5 minutes. Supernatant was removed and 
placed in a new 1.5ml tube at which point the a 1:100 dilution of a rabbit polyclonal anti-
ERa antibody was added for IP. Tubes were rotated overnight at 4 °C. 
After an overnight rotation, 50 J.tl of a 50% slurry of Protein A beads was then added to 
the tubes and rotated 1 hour at 4 °C. Finally, bound beads were washed three times with 
the lysis buffer above [with PMSF and PI added just before washes], and twice with 150 
mM NaCl. Beads were resuspended in 30 J.tl of2x SDS loading buffer, boiled 4 minutes 
and loaded on 8% SDS-polyacrylamide gel. ERa TNT lanes contained 2J.tl (between 
100,000 to150,000 cpm) of [35S] methionine-labeled in vitro translated ERa and 30 J.tl 
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SDS loading buffer. Gels were run for approximately 1.5 hours at 30 rnA in order to 
allow full separation of protein components. After proteins were run on the SDS gel, the 
gel was washed 3-4 times, shaking, in IX transfer buffer for 15 minutes. Proteins were 
then transferred to a Hybond-ECL nitrocellulose membrane (Amersham) for 2 hours at 60 
V .. The blot was then shaken in 5% skim milk powder/lX TBT-T [20mM Tris pH7.6, 
13 7 mM NaCl, 0.1% Tween-20, dH20], at room temperature for 2 hours. 
Western blot analysis for IP samples was performed with a 1 :200 dilution of an anti-
Myc antibody in 5% skim milk powder/1X TBS-T. Blots were shaken overnight at 4 oc 
and then washed 4-5 times in 1 hour at room temperature in 1X TBS-T. Blots were then 
shaken 1 hour at room temperature in a 1:3000 dilution of a sheep anti-mouse conjugated 
to HRP secondary antibody in 5% skim milk powder/lX TBS-T. Finally, blots were 
washed 4-5 times in 1X TBS-T, shaking for 1 hour, at room temperature. Samples were 
analyzed with chemiluminescent detection using ECL Plus Western Blotting System and 
Hyperfilm ECL from Amersham Technologies. Western Blot analysis of pure protein 
extracts, were completed as above. 
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2.7 :NonJiransfectetf9dCP-7 Cells: Immunoprecipitation antflmmno6Cottino 
MCF-7 cells were seeded at 1.5 x I06 MCF-7 cells/IOOmm plate, in phenol red free (PRF) 
DMEM with IO% charcoal stripped FCS. Two IOO mm plates were used for each IP. 
Cells were grown for 48 hours in phenol red free (PRF) DMEM with IO% charcoal 
stripped FCS and exposed to either I o-9 M estradiol (E2) , or an equal volume of ethanol 
(vehicle), for 6 hours prior to harvesting with IX Triton Solution [1M PMSF and IX PI; 
added to buffer immediately before IP]. Plates were washed with IO mllX PBS then 500 
J..Ll of IX Triton solution was added to each plate. Cells were scraped and allowed to sit on 
ice for 20 minutes. Lysate was pulled through a syringe ~ I5 - 20 times and lystate from 
two I OOmm plates was transferred to a 1.5ml tube. Insoluble material was removed by 
centrifugation at I6,000 x g, 4 °C, 5 minutes. Supernatant was removed and placed in a 
new I.5ml tube at which point a 1: I 00 dilution of anti-pan hMI-ERI antibody or I :50 
dilution ofanti-hMI-ERia or P- specific antibodies [produced in our laboratory, (Paterno, 
et al., 2002)] was added. Anti-hMI-ERI antiserum was prepared by immunizing rabbits, 
as in Ryan and Gillespie (1994), with the following synthetic peptides: i. pan hMI-ERl: 
I6 - CSDDHEFGPSTDML VHD - 32; ii. a-specific: 4I3 - CQMLLPVHFSAISSR- 426; 
iii. P-specific: 466 - CDFDEKSERP AKRRRV - 480. Tubes were rotated overnight at 4 
°C. 50 J..Ll of a 50% slurry of Protein A beads was then added to tubes and rotated I hour 
at 4 °C. Bound beads were washed three times with IX Triton Solution, and twice with 
150 mM NaCl. Beads were resuspended in 30 J..!l of2x SDS loading buffer, boiled 4 
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minutes and loaded on 8% SDS-polyacrylamide gel. ERa TNT lanes contained 2111 
(between IOO,OOO toi50,000 cpm) of [35S] methionine-labeled in vitro translated ERa: 
and 30 111 SDS loading buffer. After proteins were run on the SDS gel, the gel was 
washed 3-4 times, shaking, in IX transfer buffer for I5 minutes, then proteins were 
transferred to a nitrocellulose membrane, as above. The blot was then shaken in 5% skim 
milk powder/lX TBT-T [20mM Tris pH7.6, 137 mM NaCI, 0.1% Tween-20, dH20], at 
room temperature for 2 hours. Western blot analysis for IP samples was performed with 
a I :800 dilution of a mouse monoclonal anti-ERa: (Santa Cruz; sc-8005) antibody in IX 
TBS-T. Blots were shaken overnight at 4 oc and then washed 4-5 times in I hour at 
room temperature in IX TBS-T. Blots were then shaken I hour at room temperature in a 
1:3000 dilution of sheep anti-mouse conjugated to HRP secondary antibody in IX TBS-
T. Finally, blots were washed in IX TBS-T, shaking, for 1 hour at room temperature. 
Samples were analyzed with chemilurninescent detection using ECL Western Blotting 
System and Hyperfilm ECL from Amersham Technologies. 
Western Blot analysis of pure protein extracts, were completed as above except for 
verification of endogenous hMI-ERI , the nitrocellulose membrane was shaken in 5% 
skim milk powder/ IXTBS-T for two hours and then for 2 hours in a I :2500 dilution of 
anti-pan hMI-ERI antibody in 0.5% skim milk powder/lX TBS-T. The membrane was 
washed 4 to 5 times, shaking 1 hour in 0.5% skim milk powder/ IX TBS-T, then shaken 
in I :2500 dilution of donkey anti-rabbit HRP secondary antibody in 0.5% skim milk 
powder/IX TBS-T. Finally, membranes were washed 1 hour, shaking, in IX TBS-T. 
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2. 8 CReporter Assays 
2. 8.1 L uciferase }lssays 
For luciferase assays, 3.0 x 105 MCF-7 cells/well were seeded in 6-well plates in PRF 
DMEM - 18 hours prior to transfection. For the frrst set ofluciferase assays, cells were 
transiently transfected with 0.5 J.!g ofvERE(3)TKLuc reporter plasmid and 0.5 j.lg of 
either pCS3+MT, pCS3+MT-hmi-erla, or pCS3+MT-hmi-erl~. The second set of 
luciferase assays were completed with 0.8 j...lg of pS2-ERELuc, or 0.8 j.lg pS2ilERELuc 
reporter plasmids and 0.8 j.lg of either pCS3+MT, pCS3+MT -hmi-er I a or pCS3+MT-
hmi-erl~. Cells were treated with 10-9 M E2 [Sigma], or an equivalent volume of ethanol, 
for 48 hours after transfection. MCF -7 cells were collected by trypsinization as follows: 
medium was aspirated, cells were washed with 2m11X PBS per well. PBS was aspirated 
off cells and 200 J.!l of trypsin (Gibco) was added per well. Tyrpsin was left on cells for 
approximately 6 minutes at which point 1 m1 ofDMEM (plus serum) was added to the 
well. Medium was pipetted up and down to break up cell clusters and the lml was then 
placed into an Eppendorf tube. Tubes with trypsinzed cells were then centrifuged at 600 x 
g for 8 minutes. Supernatant was aspirated and the pelleted cells were stored at -70 °C. 
To prepare cell lysate, 100 j...Ll of IX Reporter Lysis Buffer (E3971 , Promega) was added 
to the pelleted cells. The Eppendorf tube was vortexed in order to resuspend pelleted 
cells. Cells and lysis buffer were incubated on ice for a minimum of 30 minutes. During 
this time, luciferase assay substrate (Promega) was removed from -70 oc and allowed to 
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come to room temperature. After the 30 minute incubation, the lysed cells were re-
vortexed and spun at 16,000 x g for two minutes at 4°C. Supernatant was removed and 
placed into new tubes. Luciferase assays were performed by mixing 20 ~-tl of the cell 
lysate with 100 ~-tl of luciferase assay substrate and by using a Monolight 2010 
Luminometer (Analytical Luminescence Laboratory). The relative luciferase units (RLU) 
were normalized to the amount of cellular protein (assayed as outlined below) in each 
sample and plotted, in order to account for possible variations between experimental 
samples. A control vector, such as ~-galactosidase, is sometimes used in such 
experiments to normalize for transfection efficiency. Such a control was not used in this 
case, however, due to the fact that h.MI-ER1 is known to interact with transcriptional 
regulatory components such as HDACs and CBP/p300. Endogenous or transfected h.MI-
ER1 could, therefore, interfere with the transcription, translation and/or activity of~­
galactosidase, rendering it an inefficient measure for transfection efficiency. Each 
experiment was repeated two to three times, as indicated. 
2. 8. 2 CBioraa }lssays 
Biorad assays were completed in order to determine the amount of protein present in each 
cell lysate. To calibrate the spectrophotometer, 4 ~-tl of 1X lysis buffer was mixed with 
796 ~-tl dH20 and 200 ~-tl Biorad reagent. For samples ofBSA, five different amounts of 
BSA were used (1.4, 2.8, 5 .6, 8.4 or 11.2 11g) along with 4 ~-tl of IX lysis buffer for each 
sample. dH20 was added to bring this volume up to 800 ~-tl, at which point 200 ~-tl of 
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Biorad reagent was added to each reaction. For each sample, 4 111 of cell lysate was 
mixed with 796 111 of dH20 and 200 111 of Biorad reagent. All reactions were left at room 
temperature for a minimum of 1 0 minutes and all readings were completed in a 
spectrophotometer at a wavelength of 595nm. 
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3. Results: 
3.1 In o/itro Interaction ofli9ri.I-P.<R1 Witli o/arious :NucCearJfonnone 'Receptors 
In order to investigate whether hMI-ERl ex or hMI-ERl ~ interact with nuclear 
hormone receptors, a series of GST -pull down assays were performed using in vitro 
translated 35S-labeled ERcx, RARcx, RAR~, RARy, RXRcx, or RXRy receptors and GST-
hMI-ER1cx or GST-hMI-ER1~ fusion proteins. Preliminary GST-pull down assays 
revealed that both GST-hMI-ER1cx and GST-hMI-ER1~ interact with each receptor. 
Further GST-pull down assays were then completed to determine the amount ofGST-
fusion protein required for interaction of GST -hMI-ER1 with each of the receptors. In 
vitro translated 35S-labeled HDAC was also used as a positive control in a number of the 
GST- pull down assays completed. 
A series of GST -pull down assays were completed with serial dilutions of GST-
MI-ER1~ (0.25, 0.5, 1, or 2 1-1g) and a constant amount of in vitro translated 35S-labeled 
receptor (ERcx, RARcx, RAR~, RARy, RXRcx, or RXRy) [100,000 cpm]. Each assay was 
repeated twice. The in vitro translated 35S-labeled receptors did not interact with GST 
alone, however, full length hMI-ER1 ~was found to interact, in a dose dependent manner, 
with each of the nuclear hormone receptor listed (Figures 4- 9, respectively). These 
results demonstrated that hMI-ER1~ interacts with ERcx, RARcx, RAR~, RARy, R.XRcx, 
and RXRy. For all subsequent GST-pull down assays, 1 1-1g of full length GST-hMI-
ERlcx or GST-hMI-ER1~ was used. 
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Figure 4: hMI-ERlP interacts with ERa in vitro. 
<ERa 
GST-pull down assays were performed by incubating in vitro translated 35S-labeled ERa. 
protein (100,000 cpm) with 0.25 J.!g, 0.5 J.!g, 1 J.!g, or 2 Jlg ofGST alone or GST-MI-
ERI p. An autoradiography of a dried SDS-polyacrylamide gel is shown with the 
positions of the marker proteins indicated on the left. The position of ERa. (approximately 
65.5 kDa) was determined by running an in vitro translated 35S-labeled ERa. along side 
samples. 
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Figure 5: hMI-ERl~ interacts with RARa in vitro. 
<RARa 
GST -pull down assays were performed by incubating in vitro translated 35S-labeled 
RARa protein (100,000 cpm) with 0.25 J.lg, 0.5 J.lg, 1 J.lg or 2 J.lg ofGST alone or GST-
MI-ER1~. An autoradiography of a dried SDS-polyacrylamide gel is shown with the 
positions of the marker proteins indicated on the left. The position of RARa 
(approximately 50.1 kDa) was determined by running an in vitro translated 35S-labeled 
RARa along side samples. 
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Figure 6: hMI-ERlP interacts with RARP in vitro. 
<RAR~ 
GST -pull down assays were performed by incubating in vitro translated 35S-labeled 
RARP protein (1 00,000 cpm) with 0.25 flg, 0.5 flg , 1 flg or 2 flg of GST alone or GST-
MI-ERI P. An autoradiography of a dried SDS-polyacrylamide gel is shown with the 
positions of the marker proteins indicated on the left. The position of RARP 
(approximately 50.0 kDa) was determined by running an in vitro translated 35S-labeled 
RARP along side samples. 
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Figure 7: hMI-ERlP interacts with RARy in vitro. 
<RARy 
GST -pull down assays were performed by incubating in vitro translated 35S-labeled 
RARy protein (100,000 cpm) with 0.25 J.lg, 0.5 J.lg, 1 J.lg or 2 J.lg ofGST alone or GST-
MI-ERlP. An autoradiography of a dried SDS-polyacrylamide gel is shown with the 
positions of the marker proteins indicated on the left. The position of RAR y 
(approximately 50.0 kDa) was determined by running an in vitro translated 35S-labeled 
RAR y along side samples. 
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Figure 8: hMI-ERlP interacts with RXRa in vitro. 
GST-pull down assays were performed by incubating in vitro translated 35S-labeled 
RXRa protein (100,000 cpm) with 0.25 11g, 0.5 11g, 1 11g or 2 11g ofGST alone or GST-
MI-ER1 p. An autoradiography of a dried SDS-polyacrylamide gel is shown with the 
positions of the marker proteins indicated on the left. The position of RXRa 
(approximately 51.4 kDa) was determined by running an in vitro translated 35S-labeled 
RXRa along side samples. 
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Figure 9: hMI-ERlP interacts with RXRy in vitro. 
<RXRy 
GST -pull down assays were performed by incubating in vitro translated 35S-labeled 
RXRy protein (100,000 cpm) with 0.25 f.lg, 0 .5 f.lg, 1 f.lg or 2 f.lg ofGST alone or GST-
MI-ERl p. An autoradiography of a dried SDS-polyacrylamide gel is shown with the 
positions of the marker proteins indicated on the left. The position of RXR y 
(approximately 5l.OkDa) was determined by running an in vitro translated 35S-labeled 
RXR y along side samples. 
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3.1.1 Ligand Independent Interaction ofli:MI-P/R1 andCJ?Jl_(Ra or1ULCRB In Vitro 
The binding of a ligand to a nuclear hormone receptor will change the 
receptor conformation and, in many cases, will lead to subsequent changes in nuclear 
receptor interacting partners. Therefore, in order to investigate whether the interaction 
between hMI-ER1a. or hMI-ER1P and RARa. or RARP would be affected by the 
presence of ligand (RA), GST -pull down assays with 1 o-6 M RA, or an equal volume of 
DMSO (vehicle), were conducted and repeated three times. GST, GST-MI-ER1a. or 
GST-MI-ER1P were incubated with GST beads as above. After 5 washes with GST 
buffer, GST-bound beads were resuspended with GST buffer with RA, or an equal 
volume of DMSO (vehicle), and 100,000 cpm of in vitro translated 35S-labeled receptor. 
As shown in figures 1 0 and 11, the presence of RA did not affect the interaction between 
hMI-ER1a. or hMI-ER1P and either ofthe receptors. These results indicate that the in 
vitro interaction between hMI-ER1a. or hMI-ER1P and RARa or RARP is ligand-
independent. 
3.1.2 Ligand Independent Interaction ofli:MI-P/R1 andP/Ra In Vitro 
To investigate whether the interaction between hMI-ER 1 a. or hMI-ER 1 p and ERa. 
would be affected by the presence of ligand (E2), GST -pull down assays were repeated 
four times with 1 o-6 M E2, or an equivalent volume of ethanol (vehicle). A representative 
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gel is shown in figure 12. Results from each GST-pull down assay completed 
demonstrated that both hMI-ER1cx and hMI-ER1P interact with ERa in vitro, in a ligand-
independent manner. 
Two GST-pull down assays were also completed where E2 was pre-incubated with 
35S-labeled ERa before being added to the GST-bound beads, in order to determine if the 
interaction between hMI-ER1cx or hMI-ER1P and ERa would be affected by the 
conformational change induced in ERa upon the binding of ligand. Figure 13 shows that 
pre-incubation of E2 and ERa did not affect the in vitro interaction between hMI-ER 1 ex or 
hMI-ER1P and ERa. 
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Figure 10: Ligand independent interaction between hMI-ERlu and hMI-ERlP 
with RARu in vitro. 
GST-pull down assays were completed with 35S-labeled RARa protein (100,000 cpm) 
and 1.3 x 10-11 moles of either GST alone, GST-MIERla, or GST-MI-ERlp and 10-6 M 
retinoic acid (RA)(+) or DMSO (vehicle)(-), and repeated three times. An 
autoradiography of a dried SDS-polyacrylamide gel is shown with the positions of the 
marker proteins indicated on the left. The RARa input lane represents 10% of the input of 
35S-labeled RARa protein used in each pull down assay. 
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Figure 11: Ligand independent interaction between hMI-ERla and hMI-ERlP 
with RARP in vitro. 
GST-pull down assays were completed with 35S-labeled RARP protein (100,000 cpm) 
and 1.3 x 10-11 moles of either GST alone, GST-MIERla, or GST-MI-ER1P and 10-6 M 
retinoic acid (RA)(+) or DMSO (vehicle)(-), and repeated three times. An 
autoradiography of a dried SDS-polyacrylamide gel is shown with the positions of the 
marker proteins indicated on the left. The RARP input lane represents 10% of the input 
of 35S-labeled RARP protein used in each pull down assay. 
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Figure 12: Ligand independent interaction between hMI-ERla and hMI-ERlP with 
ERa in vitro. 
GST-pull down assays were completed with 35S-labeled ERa protein (100,000 cpm) and 
1.3 x 10·11 moles of either GST alone, GST -MIERl a, or GST -MI-ERl p and 10·6 M 
estradiol (E2) (+)or ethanol (vehicle)(-), and repeated four times. An autoradiography of 
a dried SDS-polyacrylamide gel is shown with the positions of the marker proteins 
indicated on the left. The ERa input lane represents 10% of the input of 35S-labeled ERa 
protein used in each pull down assay. 
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Figure 13: Pre-incubation of E2 and ERa does not alter the interaction between 
hMI-ERla or hMI-ERlP with ERa in vitro. 
GST -pull down assays were completed by incubating 1.3 x 1 o-'' moles of GST alone, 
GST-MIER1a, or GST-MI-ER1P with GST beads, rotating one hour, at 4°C. 35S-labeled 
ERa protein (100,000 cpm) and 10-6 M estradiol (E2)(+) or ethanol (vehicle)(-) were pre-
mixed and incubated together for 15 minutes, before being added to the GST-bound 
beads. An autoradiography of a dried SDS-polyacrylamide gel is shown with the 
positions of the marker proteins indicated on the left. The ERa input lane represents 10% 
of the input of 35S-labeled ERa protein used in each pull down assay. 
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3.1.3 crfie Jlmino JI.cidS ofli9vtl-P/R1 CRequireafor Interaction witli P/R a are Locatea 
in tlie region 325-357 
Previous studies have indicated that hMI-ERllevels are increased in breast 
tumour cells and tissues [Paterno, et al., 1998]. Given the importance ofER in breast 
cancer, subsequent studies for this research focused on characterizing the interaction 
between hMI-ER1 and ERa. In order to determine which region ofhMI-ER1a or~ is 
responsible for the interaction with ERa in vitro, GST-hMI-ER1 deletion constructs, 
expressed and purified from E. coli BL21, were used in a series ofGST-pull down assays 
with in vitro translated 35S-labeled ERa. Each GST -pull down assay was repeated four 
times. 
The complete amino acid sequence ofhMI-ERla, shown in figure 14, indicates 
the locations of the ELM2, SANT and LXXLL domains. The first series of constructs 
included fusion proteins consisting of the acidic acid domain ( aa 1-155), the ELM2 
domain (aa 164-283), the acidic activation and ELM2 domains (aa 1-283), the SANT 
domain and a C-terminus (aa 287-433) or the SANT domain and the~ C-terminus (aa 
286-512) (Figure 15A). The interaction between these constructs and ERa was compared 
to the interaction between full length GST-hMI-ER1a or GST-hMI-ER1~ and ERa. 
Figure 15B shows a representative GST -pull down assay. There was no interaction 
between any ofthe N-terminal GST-hMI-ER1 constructs (aa 1-155, 164-283 or 1-283) 
and ERa (Figure 15B). A strong interaction was observed between hMI-ER1 C-terminal 
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constructs (aa 287-433 and 286-512) and ERa (Figure 15B). Results indicate that it is the 
C-terminal region ofhMI-ER1 that is responsible for the interaction with ERa. These 
results also highlight the fact that the interaction between hMI-ER1 and ERa does not 
occur through the LXXLL motif, since both hMI-ER1a and~ interact with ERa. 
To further defme the region responsible for the interaction between ERa and hMI-
ER1, GST-pull downs assays were completed with GST-hMI-ER1 deletion constructs 
including the SANT domain and extending to the a C-terminus (aa 287-433 ), the SANT 
domain and extending to the end of the common region (aa 287-410 ), including the 
SANT domain and amino acids C-terminal to-the SANT domain (aa 287-357 ), lacking 
the last amino acid of the SANT domain (aa 287-330), including the last seven amino 
acids of the SANT domain and extending through to the a C-terminus (aa 325-433 ), and 
lacking the SANT domain and including the a C-terminus (aa 355-433) (Figure 16A). 
A strong interaction was observed between ERa and GST-hMI-ER1 constructs aa 287-
433, aa 287-410, and aa 287-357, all of which had an intact SANT domain as well as 
amino acids downstream of the SANT domain. An interaction was also observed 
between ERa and the GST-hMI-ER1 construct aa 325-433. However, deletion of the last 
aa of the SANT domain (K), and amino acids flanking the C-terminus of the SANT 
domain (aa 287-330 or aa 355-433), completely abolished interaction with ERa (Figure 
16B). This deletion analysis revealed that the sequence required for the interaction with 
ERa can be found in the region aa 325-357 ofhMI-ERl , encompassing the last seven 
amino acids of the SANT domain and amino acids flanking the C-terminus of the domain. 
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MAEPSVESSSPGGSATSDDHEFDPSADMLVHDFDDERTLEEEEMM 45 
EGETNFSSEIEDLAREGDMPIHELLSLYGYGSTVRLPEEDEEEEE 90 
EEEEGEDDEDADNDDNSGCSGENKEENIKDSSGQEDETQSSNDDP 135 
SQSVASQDAQEIIRPRRCKYFDTNSEVEEESEEDEDYIPSEDWK~ 180 
EIMVGSMFQAEIPVGICRYKENEKVYENDDQLLWDPEYLPEDKVI 225 
IFLKDASRRTGDEKGVEAIPEGSHIKDNEQALYELVKCNFDTEEA 270 
LRRLRFNVKAAREELSVWTEEECRNFEQGLKAYGKDFHLIQANKV 315 
RTRSVGECVAFYYMWKKSERYDFFAQQTRFGKKKYNLHPGVTDYM 360 
DRLLDESESAASSRAPSPPPTASNSSNSQSEKEDGTVSTANQNGV 405 
SSNGPGILQMLLPVHFSAISSRANAFLK 433 
i 
Figure 14: Complete amino acid sequence of hMI-ERla. 
The complete amino acid sequence ofhMI-ERla (N3a; aa 1-433) is shown, with 
amino acid numbers indicated on the right. The ELM2 domain is underlined, the 
SANT domain is indicated in bold and the LXXLL motif is indicated in pink. The 
arrow indicates the beginning of the a C-terminus. 
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Figure 15: ERa interacts with the C-terminal regions of hMI-ERla and hMI-ERlP 
in vitro. 
A. Schematic representing GST deletion constructs. The names of each construct, 
followed by the amino acid numbers present in respective construct, are indicated on the 
left of each construct. The acidic activation domain, ELM2 and SANT domains as well as 
alternate ex and p C-termini are indicated. 
B. In vitro translated 358-labeled ERa protein (1 0,000 cpm) was loaded directly onto the 
gel (lane 1 ). For each pull down assay, in vitro translated 358-labeled ERa protein 
(100,000 cpm) was incubated with GST alone (lane 2), GST-MI-ERlcx (lane 3), GST-MI-
ER1P (lane 4), or with deletion constructs .15, .113, .14, .19, or .116 (lanes 5, 6, 7,8, and 9 
respectively). An autoradiography of a dried SDS-polyacrylamide gel is shown with the 
positions of the marker proteins indicated on the left. The ERa input lane represents 10% 
of the input of35S-labeled ERa protein used in each pull down assay. 
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Figure 16: The ERa interaction domain is located within the region of amino acids 
325-357 of hMI-ERl in vitro. 
A. Schematic representing GST deletion constructs. Amino acid numbers present in 
respective constructs are given. 
B. In vitro translated 35S-labeled ERa protein (10,000 cpm) was loaded directly onto the 
gel (lane 1). GST pull down assays were completed with in vitro translated 35S-labeled 
ERa protein (100,000 cpm) and GST-~9, GST-~17, GST-~18, or GST-~19, GST-~10, 
or GST-~11 (lanes 2- 7, respectively). An autoradiography of a dried SDS-
polyacrylamide gel is shown with the positions of the marker proteins indicated on the 
right. The ERa input lane represents 10% of the input of 35S-labeled ERa protein used in 
each pull down assay. 
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3.2 In 'Vivo Interaction ojli:MI-P.lR1 anaP.lR a 
3.2.1/i:MI-P.CRJO antffi:MIJE1Vf3 interact witfi 1£/RO. in :MCP-7 ce[fs 
To investigate whether the interaction observed between hMI-ER1 ex or hMI-ER1 P 
and ERa in vitro would also occur in vivo, a human ER (+)breast cancer cell line (MCF-
7), was transiently transfected with pCS3+MT vector (Myc-tagged vector), pCS3+MT-
hmi-er 1 a, or pCS3+MT-hmi-er 1 fl. Transfection experiments were repeated numerous 
times under varying conditions (ie: altering concentration of plasmid or antibody, 
different buffers, varying length of time for E2 treatment, etc.) in order to optimize cell 
growth conditions and to examine whether fmal results would be affected. Cells were 
subjected to treatment with 1o-9 M E2 dissolved in ethanol, or an equal volume of ethanol 
alone, for 6 hours (repeated four times) or 48 hours (repeated six times) prior to 
extraction. Results did not vary by changing the exposure time to E2 • A representative 
blot of a 48 hour E2-treatment is shown in Figure 17. Expression ofMyc-tagged hMI-
ER1cx and Myc-tagged hMI-ER1P was verified for each experiment by Western blot 
analysis, of whole cell extracts, with an anti-Myc antibody (Figure 17 A) whereas 
expression of endogenous ERa was verified for each experiment with an anti-ERa 
antibody (Figure 17B). Cell extracts were also subjected to immunoprecipitation with 
anti-Myc antibody, followed by Western blot analysis with anti-ERa antibody. Both 
hMI-ER1cx and hMI-ER1P immunoprecipitated with endogenous ERa, in MCF7 cells, 
but only in the absence of ligand (Figure 17C). Altering the amounts of antibody used, 
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changing the exposure time to E2, and co-transfection of both hMI-ERl and ERa all 
garnered the same result (data not shown). These studies demonstrated an in vivo 
interaction between hMI-ERla or p and ERa. 
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Figure 17: hMI-ERla and hMI-ERl~ interact with ERa in the absence ofE2, in 
MCF -7 cells. 
A. MCF -7 cells were grown in PRF DMEM for approximately 18 hours. Cells were 
transfected with 1 flg ofpC83+MT vector, pC83+MT-hmi-erla or pC83+MT-hmi-erl~ 
and, after approximately 48 hours, were treated for 6 hours with 1 o-9 M E2, or an equivalent 
volume of ethanol. Celllysates were prepared and loaded directly on the gel (lanes 3 - 8). 
Western blot analysis with anti-Myc antibody followed. 358-labeled in vitro translated 
Myc-tagged hMI-ER1cx or Myc-tagged hMI-ER1P (~ 100,000 cpm) were loaded directly on 
the gel (lanes 1 and 2) to indicate the position of ERa in the cell extracts. The position of 
marker proteins are indicated. 
B. Celllysates ofMCF-7 cells transfected with 1 flg ofpC83+MT vector, pC83+MT-hmi-
erlcx or pC83+MT-hmi-erl~ and treated for 6 hours with 10-9 M E2, or an equivalent 
volume of ethanol, were prepared and loaded directly onto the gel, which was followed by 
Western blot analysis with monoclonal anti-ERcx antibody. ERa was expressed but, as 
expected, ERa was slightly downregulated by the treatment of cells with E2 [8aceda, et al., 
1988]. 358-labeled in vitro translated ERcx (~ 100,000 cpm) was loaded directly on the gel 
(lane 1) to indicate the position of ERcx in the cell extracts. The position of marker proteins 
are indicated on the left. 
C. Celllysates from MCF -7 cells, transiently transfected with 1 flg of C83+MT vector, 
pC83+MT-hmi-erlcx, or pC83+MT- hmi-erlP were prepared and subjected to IP with anti-
Myc antibody (1 :25); western blot analysis was performed using a polyclonal anti-ERcx 
antibody (1: 1 000). Cells were treated with 1o-9 M E2, or an equal volume of ethanol 
(vehicle), prior to cell lysis. 358-labeled ERa protein (1 00,000 cpm, lane 1) and cell lysate 
from non-transfected MCF -7 cells, treated with 1 o-9 M E2 (lane 2), were added directly to 
sample buffer and used to indicate the position ofERcx in the cell extracts. Protocols were 
repeated four times. The position of marker proteins are indicated on the left. 
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3.2.2 Interaction CJ3etween r.Enaooenous li:M.I-C£CR1 anar.ECRa Proteins in :JvlCP-7 Ce{{s 
In order to exclude the possibility that the observed interaction was an artifact of 
overexpression, the next three sets of experiments were conducted in order to determine if 
endogenous hMI-ER1a or hMI-ER1~ would interact with endogenous ERa in 
untransfected MCF -7 cells. MCF -7 cells were simply grown in phenol red free (PRF) 
DMEM and subjected to treatment with 1o-9 M E2, or an equal volume of ethanol, for 6 
hours prior to extraction. Cell extracts were either loaded directly (Figure 18, lanes 2 and 
3) or subjected to immunoprecipitation with a pan-hMI-ERl antibody (Figure 18, lanes 4 
and 5), pre-immune serum (Figure 18, lanes 6 and 7) or polyclonal anti-ERa antibody 
(Figure 18, lanes 8 and 9). Western blot analysis with a monoclonal anti-ERa followed. 
In this case, hMI-ER1 a and hMI-ER1~ interacted with ERa in a ligand independent 
manner, unlike earlier in vivo interaction analyses but similar to in vitro results. 
Co-immunoprecipitation was also performed using anti-hMI-ER1a-specific or 
anti-hMI-ER1~-specific antibodies for immunoprecipitation (Figure 19, lanes 1- 4). 
These results were consistent with previous in vivo interaction analyses with transfected 
MCF-7 cells (Figure17C), where hMI-ERla and hMI-ERl~ only immunoprecipitated 
with endogenous ERa in the absence of ligand. 
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Figure 18: IP ofMCF-7 celllysates with hMI-ERl antibody shows that endogenous 
hMI-ERl interacts in vivo with endogenous ERa, in a ligand independent manner. 
Non-transfected MCF-7 cells were grown in PRF DMEM and charcoal-stripped FCS for 
-72 hours and treated with 10-9 M E2, or an equal volume of ethanol (vehicle), for 6 hours 
prior to harvesting, as indicated. Celllysates were prepared and added directly to sample 
buffer (lanes 2 and 3) or subjected to IP with anti-hMI-ER1 antibody (1:100; lanes 4 and 
5), IP with pre-immune serum (1: 1 00; lanes 6 and 7), or IP with polyclonal anti-ERa 
(1: 1 00; lanes 8 and 9); western blot analysis was completed with monoclonal anti-ERa 
(1:800). 35S-labeled ERa protein (100,000 cpm) was used to verify the identity ofthe 
bands in the cell extracts (lane 1 ). The position of marker protein is indicated on the left. 
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Figure 19: IP ofMCF-7 celllysates with hMI-ERla-specific or hMI-ERlP-specific 
antibody shows that endogenous hMI-ERla and hMI-ERlP interact in vivo with 
endogenous ERa, in the absence of E2• 
Non-transfected MCF-7 cells were grown in PRF DMEM and charcoal-stripped FCS for 
- 72 hours and treated with 1 o-9 M E2, or an equal volume of ethanol (vehicle), for 6 hours 
prior to harvesting, as indicated. Celllysates were prepared and added directly to sample 
buffer (lanes 7 and 8) or subjected to IP with anti-hMI-ERlj3-specific antibody (1 :50; 
lanes 1 and 2), anti-hMI-ER1a-specific antibody (1:50; lanes 3 and 4), or polyclonal 
anti-ERa (1: 1 00; lanes 5 and 6); western blot analysis was completed with monoclonal 
anti-ERa (1 :800). The position of marker protein is indicated on the left. 
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3.2.3 li:MI-P/JUa and li:MI-'E~1[3 interact witli 'E~a in J{'£1( 293 Ce{Cs 
Different cell lines have varying expression profiles and can thus behave 
differently. For example, ERa. is found in the cell membrane, cytoplasm and the nucleus 
ofMCF7 cells [Parikh, et al., 1987] and in a study conducted by Paterno, et al., 1998, 
hMIER1 was expressed in nine breast carcinoma cell lines and eight breast tumour tissue 
samples, but, was not detectable in normal breast cell lines and breast tissues. To verify if 
the in vivo interaction between hMI-ER1a. or hMI-ER1P and ERa. would differ in another 
cell line, in vivo studies were repeated, five times, using HEK 293 cells (human 
embryonic kidney cells). HEK 293 cells were transiently transfected with pcDNA3-ERa 
and either pCS3+MT vector, pCS3+MT-hmi-erl a, or pCS3+MT-hmi-erl,Band subjected 
to treatment with 1o-9 M E2, or an equal volume of ethanol, for 6 or 48 hours prior to 
extraction (6 hour E2 treatment shown in Figure 20). Expression ofMyc-tagged hMI-
ER1a. and Myc-tagged hMI-ER1P was verified for each experiment by Western blot 
analysis with an anti-Myc antibody (Figure 20B) and expression of ERa. was verified for 
each experiment with an anti-ERa. antibody (Figure 20C). Cell extracts were subjected to 
immunoprecipitation with anti-ERa antibody followed by Western blot analysis with 
anti-Myc antibody (Figure 20A). Both hMI-ERla and hMI-ER1P interacted with ERa in 
HEK 293 cells the presence or absence ofE2, however, interaction between hMI-ER1a 
and ERa appear to be stronger in the absence ofE2• 
All of the in vivo studies show that hMI-ER1 a and hMI-ER1 p consistently 
interact with ERa, in the absence ofE2• There was a difference, however, with the 
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presence ofE2• As summarized in Table 3, no interaction was observed between hMI-
ERla or hMI-ERlP and ERa in the presence ofE2 in MCF-7 cells with protocols using 
anti-Myc, anti- hMI-ERla-specific or anti-bMI-ERlP-specific antibodies for 
immunoprecipitation. An interaction between hMI-ERla or hMI-ERlP and ERa, in the 
presence ofE2, was detected in MCF-7 cells when an anti-pan-hMI-ERl antibody was 
employed for immunoprecipitation. An interaction between hMI-ERla or hMI-ERlP 
and ERa, in the presence ofE2, was also detected in HEK 293 cells when an anti-ERa 
antibody was used for immunoprecipitation. 
T bl 3 S a e . ummaryo f ll Vi. R ult n lVO es s 
IP Antibody WBAntibody 
- E2 +E2 
Transfected anti-Myc anti-ERa + -
MCF-7 Cells 
Non- anti-pan-bMI- anti-ERa + + 
Transfected ERl 
MCF-7 Cells 
Non- anti-hMI- anti-ERa + -
Transfected ERla 
MCF-7 Cells specific 
Non- anti-hMI- anti-ERa + -
Transfected ERl P 
MCF-7 Cells specific 
Transfected anti-ERa anti-Myc + + 
HEK293 
Cells 
. . [Note: "+" mdicates an mteract10n between hMI-ERl and ERa. and "-" indicates no 
interaction betweenhMI-ERl and ERa) 
73 
Figure 20: hMI-ERl« and hMI-ERlP interact withER«, in the presence and 
absence of E2, in HEK 293 cells 
A. HEK 293 cells were transiently transfected with 0.4 J.lg ofpcDNA3-ERaand 0.4 J.lg of 
either CS3+MT vector, pCS3+MT-hmi-er1a, or pCS3+MT-hmi-er1p. Cells were treated 
with 10-9 M E2, or an equal volume of ethanol (vehicle), 6 hours prior to harvesting. Cell 
lysates were prepared and subjected to IP with anti-ERa antibody (1:100) (lanes 2-7); 
western blot analysis was performed using anti-Myc antibody (1: 1 000). 358-labeled Myc-
tagged hMI-ER1 a or Myc-tagged hMI-ER1 p protein (1 00,000 cpm) were used to verify 
the identity of the bands in the cell extracts (lane 1 and 8, respectively). The position of 
marker proteins are indicated. 
B. In order to verify expression of hmi-er 1 a or hmi-er 1 p in transfected HEK 293 cells, 
celllysates ofHEK 293 cells transfected with 0.4 J.lg ofpcDNA3-ERaand 0.4 J.lg of 
either CS3+MT vector, pCS3+MT-hmi-er1a, orpCS3+MT-hmi-er1P and treated for 6 
hours with 
1 o-9 M E2, or an equivalent volume of ethanol, were prepared and loaded directly on the 
gel (lanes 3- 6). Western blot analysis with anti-Myc antibody followed. 358-labeled in 
vitro translated Myc-tagged hMI-ER1« or Myc-tagged hMI-ER1P ( -100,000 cpm) were 
loaded directly on the gel (lanes 1 and 2, respectively) to verify the bands present in cell 
extracts. The position of marker proteins are indicated. 
C. In order to verify expression of ERa in transfected HEK 293 cells, celllysates ofHEK 
293 cells transfected with 0.4 J.lg ofpcDNA3-ER a and pCS3+MT-hmi-er1P and treated 
for 6 hours with 1 o-9 M E2, or an equivalent volume of ethanol, were prepared and loaded 
directly on the gel. Western blot analysis with anti-ERa followed. Expression ofERa in 
cells transfected with 0.4 J.lg ofpcDNA3-ERaand 0.4 J.lg of either CS3+MT vector or 
pCS3+MT -hmi-er 1 a were also verified (data not shown). The position of marker proteins 
are indicated on the left. 
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3.3 P.ifect ofli~I-P.CR1 on P.CRP....(])riven fJ.'ranscription: 
3.3.1 li~I-tE~1~ 'Enliances P,~P,-driven CJ'ranscription in Luciferase Jlssays witfi tfie 
ifE/RP.(3,'!IRLuc reporter pfasmid 
Since both hMI-ERl a and hMI-ERl ~ were found to interact with ERa in vitro 
and in vivo, experiments were performed to determine whether this interaction affects the 
ability of ERa to bind to EREs and regulate transcription. The first reporter construct 
used for luciferase assays was vERE(3)TkLuc (Tk: thymidine kinase; Luc: luciferase). 
The estrogen response element in this construct was that of vitellogenin A2, a known E2-
responsive gene. MCF-7 cells were transfected with vERE(3)TkLuc and either pCS3+MT 
vector, pCS3+MT-hmi-erl a, or pCS3+MT-hmi-erlfJ, and treated with 10-9 M E2, or an 
equivalent volume of ethanol, for 48 hours prior to harvesting. Celllysates were 
collected and relative luciferase units (RLU) were determined and normalized to the 
amount of cellular protein in each sample. The ability ofhMI-ERla and hMI-ERl~ to 
regulate transcription can be analyzed by comparing the level of luciferase activity in 
these samples, relative to the Myc-tagged empty vector. In two separate experiments 
conducted with the vERE(3)TkLuc reporter vector, overexpression ofhMI-ERla did not 
have an effect on transcription compared to the control (vERE(3)Tkluc + CS3MT), 
whereas hMI-ERl ~ enhanced ERE-driven transcription, by approximately 3-fold, in the 
presence of E2 (Figure 21 ). 
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Figure 21: hMI-ERlj} enhances ERE-driven transcription in MCF-7 cells transfected with 
the vERETKLuc reporter construct. 
MCF-7 cells were transfected with 0.5 )-tg ofthe vERE(3)TKLuc reporter plasmid and 0.5 )-tg of 
either CS3+MT vector, pCS3+MT- hmi-er 1 a, or pCS3+MT- hmi-er 1 fJ and cultured in PRF 
DMEM with 1 o-9 M estradiol (E2), or an equal volume of ethanol (vehicle). Cells were harvested 
approximately 48 hours after transfection and the amount of relative luciferase units (RLU) was 
determined. Values were normalized to the amount of cellular protein present in each sample. 
Average values and standard deviations from two independent experiments are shown. 
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3.3.2 fi.'MI-'ECJ?1(3 'Enliances 'ECJ?'E-ariven CJ'ranscription Wliereas fi.'MI-'ECJ?la inlii6its 
'ECJ?'E-ariven CJ'ranscription in Luciferase Jl.ssays witli tlie pS2-'ECJ?'ELuc CJ?eporter 
PCasmia 
Thymidine kinase (Tk) belongs to a group of enzymes involved in DNA synthesis 
and protein synthesis. It had been demonstrated that elements in the Tk promoter contain 
sequences recognized by various protein complexes, including Sp 1 transcription factors 
[Karlseder, et al., 1996]. Since hMI-ER1 has been found to repress transcription by 
inhibiting binding ofSp1 proteins to DNA [Ding, et al., unpublished data], luciferase 
assays were completed with a different reporter construct (pS2-ERELuc) in order to verifY 
that results obtained with vERE(3)TkLuc were not altered by an interaction between hMI-
ER1 and Sp1 sites in the Tk promoter. pS2, a member of the trefoil peptide family, is a 
known ER-responsive gene that is widely used to study estrogen-regulated gene 
expression. The 5' flanking region ofthe pS2 gene contains a TATA box, CAAT box and 
an single imperfect ERE [Jeltsch, et al,. 1987; Nunez, et al., 1989; Kim, et al., 2000]. 
Estrogen receptors will interact with estrogen responsive genes containing one or more 
copies of the ERE consensus sequence (5'-GGTCAnnnTGACC'3'), or those that contain 
variants ofthis sequence, such as half sites (TGACC). The pS2-ERELuc reporter 
construct contains 1050 bp of the pS2 promoter [Berry, et al., 1989] preceding the 
luciferase reporter ofpGL3 [Tremblay, et al., 1997]. The pS2~ERELuc construct, used 
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as a control, contains the same insert in the pGL3 vector except the ERE half site was 
replaced by sequences encoding EcoRI-EcoRV sites, generated by PCR mutagenesis 
[Tremblay, et al., 1997]. Luciferase assays were performed on three separate occasions 
in MCF -7 cells, as described above, with either pS2- ERELuc, with an intact ERE, or pS2-
~ERELuc, with a mutated ERE, and either pCS3+MT vector, pCS3+MT -hmi-er 1 a, or 
pCS3+MT -hmi-er 1/3. For each luciferase assay conducted, expression of Myc-tagged 
hMI-ERla and Myc-tagged hMI-ERl~ was verified by Western blot analysis with anti-
Myc antibody. Figure 22B shows a representative Western blot. 
MCF-7 cells, transfected with the pS2-ERELuc vector alone, will display a certain 
level of luciferase activity in the presence of estrogen. In comparing the level of relative 
luciferase activity of experimental samples (pS2- ERELuc + hMI-ERl a or pS2- ERELuc + 
hMI-ERl ~)to the control (pS2-ERELuc + pCS3+MT vector), it is evident that 
overexpression ofhMI-ERl ~ enhances ERE-driven transcription almost 2 fold, whereas 
hMI-ERla inhibits ERE-driven transcription 1.6 fold (Figure 22A). 
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Figure 22: ERE-driven transcription is inhibited by hMI-ERlcx and enhanced by 
hMI-ERlP in MCF-7 cells transfected with pS2-ERELuc reporter constructs. 
A. MCF-7 cells were transfected with 0.8 !lg of either pS2-ERELuc or pS2LlERELuc 
reporter plasmids and 0.8 !lg of either CS3+MT vector, pCS3+MT -hmi-er 1 a , or 
pCS3+MT-hmi-erlP and cultured in PRF DMEM with 10-9 M estradiol (E2), or an equal 
volume of ethanol (vehicle). Cells were harvested approximately 48 hours after 
transfection and the amount of relative luciferase units (RLU) was determined. Values 
were normalized to the amount of cellular protein present in each sample. Average values 
and standard deviations from two independent experiments are shown. 
B. Expression ofMyc-tagged hMI-ERla and hMI-ERIP protein in each sample was 
verified by Western blot analysis with anti-Myc antibody. A representative Western blot 
is shown. In vitro translated 35S-labeled Myc-tagged hMI-ERla or Myc-tagged hMI-
ERIP protein (100,000 cpm) were used to verify bands in the cell extracts (lanes 1 and 2, 
respectively). The position of marker proteins are indicated. 
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3.4 fResufts Summary 
Results presented in this study confirm the hypothesis that hMI-ERla. and hMI-
ERl ~ interact with a number of nuclear hormone receptors in vitro (ERa, RARa, RAR~, 
RARy, RXRa., and RXRy) and with ERa. in vivo, and indicate that this interaction can 
affect the transcriptional regulatory function of ERa.. The interaction between hMI-ERl 
and ERa. involves a sequence contained within aa 325-357 ofhMI-ERl. Studies 
presented here highlight the importance of the last amino acid of the SANT domain and 
amino acids flanking the C-terminus of the SANT domain for this interaction. 
The interaction between hMI-ERla. or hMI-ERl~ and RARa., RAR~, or ERa. are 
not affected by the presence of ligand in vitro. In vivo studies confirm that hMI-ERl a 
and~ also interact with ERa. in the absence of estrogen, however, results varied with the 
presence ligand. hMI-ERla. and hMI-ERl~ were found to interact with ERa. in MCF-7 
cells only in the absence of ligand when anti-Myc or anti-hMI-ERla. or ~-specific 
antibodies were used for immunoprecipitaton. However, hMI-ERla. or~ interacted with 
ERa in the presence and absence of estrogen in MCF -7 and HEK 293 cells when either a 
pan-hMI-ERl or anti-Myc antibodies were employed for immunoprecipitation, 
respectively. 
Studies examining the possible functional consequences of an interaction between 
hMI-ERla. or~ and ERa. indicate that hMI-ERl~ enhances ERE-driven transcription. 
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hMI-ERl a, on the other hand, did not have an effect on ERE-driven transcription with 
the vERE(3)TkLuc reporter plasmid but had an inhibitory effect on ERE-driven 
transcription with pS2-ERELuc reporter plasmids. 
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4. Discussion: 
Nuclear hormone receptors play a critical role in the regulation of cell growth, 
differentiation and apoptosis and it has become evident that the mechanism of hormone 
receptor action is a highly complex process. The estrogen receptor (ER), for example, is 
known to exert both genomic (nuclear) and nongenomic (membrane and cytoplasmic) 
effects, some of which can be explained by cross-talk with growth factors and cellular 
kinase pathways. ER genomic activity, which involves ligand binding, receptor 
dimerization, nuclear translocation and binding of complexes to estrogen-response 
elements, has been found to be up-regulated by pathways including insulin-like growth 
factor type- I and epidermal growth factor signaling pathways [Nicholson, et al., 1999]. 
Through nongenomic effects, nuclear hormone receptors can rapidly and transiently 
initiate signaling from the cell membrane or cytoplasm, in response to their respective 
ligands, through interaction with numerous signal transduction cascades [Losel, et al., 
2003; Cato, et al., 2002]. 
Whether exerting genomic or nongenomic effects, the estrogen receptor requires 
multiple protein-protein interactions, with both basal transcriptional machinery as well as 
coregulatory molecules, in order to exert their functions in a cell. ER coregulators can 
themselves be phosphorylated by growth factors, stress-response and cytokine-related 
pathway kinases, which have been identified as yet another regulatory mechanism for ER 
signaling [Schiff, et al., 2003]. The presence of an acidic activation domain, ELM2 and 
SANT domains, as well as a proline rich motif, indicate that hMI-ERl is likely to be 
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involved in protein-protein interactions and the presence of an LXXLL motif in hMI-
ERla suggests that one possible group of protein-interacting partners could be nuclear 
hormone receptors. The purpose of this study was to determine whether hMI-ERla is 
indeed a nuclear hormone receptor coregulator and to determine whether it plays a part in 
regulating the function of the estrogen receptor in the cell. 
4.1 In vitro Interaction ofli~M..J-P.qV witli Nucfear1fonnone CReceptors: 
.. 
A series of preliminary GST pull down assays demonstrated that both hMI-ERla 
and hMI-ERl~ interact in vitro with ERa, RARa, RAR~, RARy, RXRa, and RXRy 
(Figures 4 - 9). These results indicated early on that the LXXLL-motif was not 
responsible for the in vitro interaction since hMI-ERl ~'which lacks this motif, was also 
able to interact with the nuclear hormone receptors tested. It is not uncommon for 
LXXLL-containing cofactors to interact with various nuclear hormone receptors through 
alternate motifs or through other bridging proteins. REA (repressor for E2-activity), for 
example, will interact directly with liganded ER and suppressER-activated gene 
transcription by E2, and although REA contains an LXXLL motif, this motif is not 
required for interaction withER [Martini, et al., 2003]. In the case ofmADA3, an 
LXXLL-containing protein, interaction with ERa occurs through a TBP-free-TAF 
containing complex (TFTC) [Benecke, et al., 2002]. It is the members of the TFTC 
complex that mediate the interaction with nuclear hormone receptors. ASC-2 is yet 
another LXXLL-containing protein which does not require this motif for interaction with 
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RXR, RAR, TR, ERa, and GR, or with members of basal transcriptional machinery such 
as TFIIA, TBP, CBP/p300, and SRC-1 [Lee, et al., 1999]. 
Since both hMI-ER1 a and f3 were found to interact with the nuclear hormone 
receptors in vitro, it was evident that the domain responsible for this interaction was 
located in the common region ofhMI-ERl. Therefore, hMI-ER1(3 was used in GST-pull 
down assays performed to determine whether in vitro interaction between hMI-ER1 and 
ERa, RARa, or RAR(3, would be affected by the presence of respective ligands. Results 
indicated that hMI-ER1(3 interacts, in vitro, with ERa, RARa and RAR(3 in a ligand 
independent manner (Figures 10- 13). In future, these assays could be repeated with hMI-
ER1a in order to verify that in vitro results would be consistent for both hMI-ER1 
isoforms. 
Previous studies indicated that hMI-ER1levels were increased in breast tumour 
cells and tissues, suggesting a role for hMI-ER1 in breast tumourigenesis [Paterno, et al., 
1998]. The ER is a nuclear hormone receptor with significant implications in breast 
cancer, therefore, subsequent studies for the present work focused on characterizing the 
interaction between hMI-ER1. The next goal was, thus, to determine which region of 
hMI-ER1 was responsible for interaction with ERa. Another series of GST pull down 
assays were completed where various GST-hMI-ER1 deletions constructs were tested for 
interaction with in vitro translated 35S-labeled ERa protein. These studies reveal that 
amino acids within the region of aa 325-357 of hMI-ER1 are required for the interaction 
with ERa, highlighting the significance of the end of the SANT domain and the amino 
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acids flanking the C-tenninus of the currently defmed domain for this interaction (Figures 
15 and 16). A GST-hMI-ERl construct containing only aa 325-357 ofhMI-ERl, and 
constructs with N-tenninal deletions of this region, should be used for future in vitro 
studies in order to identify the exact amino acids responsible for the interaction between 
hMI-ERl and ERa. 
It is predicted that, like the ELM2 domain, the SANT domain will turn out to be 
larger than currently hypothesized. Originally, the ELM2 domain was thought to 
encompass amino acids 180-239 ofhMI-ERl, which had been defmed based on sequence 
conservation in a few available protein sequences [Solari, et al., 1999]. However, a 
subsequent reexamination of the alignment ofhMI-ER1 and other available protein 
sequences revealed conservation of amino acid sequences C-terminal to the defmed 
ELM2 domain [Ding, et al., 2003]. Data presented in the study by Ding, et al., 2003, 
illustrated that the functional ELM2 domain extends from amino acids 180-284. A 
BLAST analysis (www.ncbi.nlm.nih.gov/BLAST/) comparing amino acid sequences of 
SANT domain containing proteins such as hMI-ERl, MTAl, MTA2, and MTA3, also 
suggests that the region ofhomology extends downstream of the originally defined SANT 
domain. 
Examining the other SANT domain containing proteins does seem to suggest a 
domain larger than the predicted 104 amino acids. For example, a region encompassing 
179 amino acids of CoREST, a previously identified corepressor for the REST/NRSF 
transcription factor (REI silencing transcription factor/neural restrictive silencing factor), 
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is responsible for its interaction with HDAC 112 and its corepressor function [You, et al., 
2001]. This 179 amino acid region contains a SANT domain such as that found in other 
HDACl/2-interacting proteins including hMI-ER1, NCoR, MTA1 and MTA2. Until 
recently, only two HDAC1/2 containing complexes had been identified: mSin3 and 
NuRD-containing complexes [You, et al., 2001]. 
The exact function of the SANT domain in transcriptional regulators still remains 
to be elucidated, however, several lines of evidence point to a role in chromatin 
remodeling since SANT domains can be found in subunits of ATP-dependent chromatin 
remodeling enzymes, histone acetyltransferases and deacetylases [Boyer, et al., 2002] . 
The identification of novel HDAC1/2-containing complexes, such as the CoREST-
HDACl/2 complex, leaves room for the possibility that other ELM2/SANT domain-
containing proteins may form such complexes and that the ELM2 and SANT domains 
could play an, as of yet, unexplained but physiologically relevant function. It has been 
demonstrated that the ELM2 domain ofhMI-ERl will bind to HDAC Yz complexes, and 
through this interaction, function as a transcriptional repressor [Ding, et al., 2003]. 
4.2 fi?dl-P.CR.1 Interacts witli P.CR.a In o/ivo 
4.2.1 Protein-Protein Interaction: 
In vivo studies demonstrated that when cell extracts from transfected and non-
transfected MCF-7 cells were immunoprecipitated with anti-Myc, anti-hMI-ERlcx-
specific or anti-hMI-ERl ~-specific antibodies, followed by immunoblotting with an anti-
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ERa antibody, both hMI-ERla and hMI-ERlP interacted with ERa, but only in the 
absence of E2 (Figures 17C and 19). However, when non-transfected MCF -7 cells were 
immunoprecipitated with anti-pan hMI-ERl antibody, followed by immunoblotting with 
an anti-ERa antibody, a ligand-independent interaction was detected between hMI-ERla 
or hMI-ERl P and ERa (Figure 18). These results could be explained by the fact that the 
anti-Myc antibody recognizes the most N-terminal end ofMyc-tagged hMI-ERl and the 
anti-hMI-ERla or P-specific antibodies recognize the most C-terminal sequences ofhMI-
ERl whereas the anti-pan-hMI-ERl antibody recognizes an amino acid sequence in the 
common region ofhMI-ERl. Perhaps, in the presence ofE2, hMI-ERl is involved in 
protein-complexes where theN- and C-termini are folded in such a way so as to prevent 
the antibody from accessing the relevant amino acids and thus an interaction cannot be 
detected through immunoprecipitation experiments. It should also be noted that each set 
of experiments were performed separately, at different times. In order to exclude the 
possibility that results were due to slight differences in experimental procedure, the 
experiments could be completed together, at the same time and run on side by side on one 
SDS gel. 
There was also a difference observed between transfected HEK 293 cells and 
transfectedMCF-7 cells. hMI-ERla and P were only found to interact with ERa in the 
absence ofE2 in transfected MCF-7 cells (Figure 17C) however, interacted in the 
presence and absence of E2 in HEK 293 cells (Figure 20A). Some critical differences 
should be noted between these sets of experiments. Firstly, MCF-7 cells were only 
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transfectedwith Myc-hMI-ERla or~ and tested for interaction with an endogenous ERa, 
however, HEK 293 cells were co-transfected with both Myc-hMI-ERla or~ and ERa. 
Secondly, immunoprecipitations were completed with anti-Myc antibodies in MCF-7 
cells followed by immunoblotting with an anti-ERa antibody whereas 
immunoprecipitations were completed with anti-ERa in HEK 293 cells followed by 
immunoblotting with an anti-Myc antibody. In order to investigate whether such 
differences are critical, results could be verified by reversing antibodies used for 
immunoprecipitation and western blotting (ex: immunoprecipitation with anti-Myc 
antibody for HEK 293 cell extracts followed by immunoblotting with an anti-ERa 
antibody). 
The ligand-independent interaction observed between hMI-ERla or~ and ERa in 
HEK 293 cells immunoprecipitated with anti-ERa could be explained by the fact that 
hMI-ERla and~ proteins would be denatured when run on an SDS gel, and thus N-
termini would be accessible to the anti-Myc antibody for immunoblotting (Figure 23). 
TheN-terminus ofhMI-ERla/~ in MCF-7 cell extracts may not have been accessible to 
the anti-Myc antibody when it was used for immunoprecipitation, prior to the denaturing 
of the proteins through SDS-P AGE. Co-transfection experiments with both ERa and 
hMI-ERla or hMI-ERl~ were completed in MCF-7 cells and the same ligand-dependent 
interaction was observed (data not shown). 
Both ERa and~ mRNA undergo alternative splicing, ultimately generating 
transcripts that have duplications or different combinations of exons [Koduri, et al., 
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Figure 23: Model to account for the different results observed for transfected HEK 
293 cells and transfected MCF-7 cells. hMI-ERl interacting proteins may be cell 
context dependent. 89 
2001]. A number of studies have shown that these splice variants are present in breast 
cancer cell lines, including MCF -7 cells. The exact functional role( s) of the splice 
variants have not been established, although several lines of evidence suggest that some 
of these variants can be translated into functionally active proteins [Koduri, et al., 2001]. 
For instance, a 77 kDa ERa protein, with duplications in exons 6 and 7, was found in an 
MCF-7 cell clone that grows optimally in the absence ofE2 [Pink, et al., 1996]. During 
the first 6 months of another study, aimed at determining the effects of long term 
exposure to the anti -estrogen, tamoxifen, a novel population of M CF-7 cells emerged that 
overexpressed an ERa protein, arising from an mRNA variant lacking exon 3, and 
ultimately encoding a protein that was missing a 39 amino acid sequence [Fasco, et al., 
2003]. 
In the future it will be important to characterize ERa expression in the MCF-7 cell 
line used in this study in order to determine if hMI-ER1 a and ~ will also interact with 
and/or affect the functioning of alternate ERa splice variants It would also be useful to 
repeat experiments in a number of other breast cancer cell lines in order to verify if the 
interactions observed between hMI-ER1 and ERa, in non-transfected MCF-7, cells will 
hold true in other breast cancer cell lines that may express other ERa variants. The 
heterogeneity of ER isoform profiles in breast cancer cell lines suggests that the 
expression of alternate ER isoforms may result in variations in response to estrogens and 
anti-estrogens, altering activation of estrogen-responsive genes and ultimately 
contributing to tumourigenesis and tumour progression. It is also likely that expression of 
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splice variants, relative to wild type ER, in a given cell line, may also influence E2-
responsiveness 
A number of studies have attempted to determine the cellular factors that 
influence the observed mechanistic differences between cell lines. Even within a 
specific cellular classification, such as ER-positive breast cancer cell lines, there is a 
variability in receptor isoform expression as well variability in coregulator, growth factor 
and protein kinase expression. Alternate expression profiles exhibited by various cells 
types could affect the interaction ofhMI-ER1 and ERa.. For example, hMI-ER1 will 
interact with transcriptional machinery that enhances transcription (CBP/p300) as well as 
with that which inhibits transcription (HDAC) . Therefore, the interaction between hMI-
ER1 and ERa. could vary depending on which hMI-ER1 and/or ERa. interaction partners 
are expressed. The observed differences in interactions between hMI-ER1 and ERa. in 
MCF-7 cells (ligand-dependent interaction) versus HEK 293 cells (ligand-independent 
interaction) in this study [Figuresl7c, 19, and 20a], therefore, is not surprising. A 
separate study confirmed that different breast cancer cell lines have different nuclear 
hormone receptor and cofactor expression profiles and showed that nuclear receptor 
regulation is cell line specific [Vienonen, et al., 2003]. For example, E2 will reduce ERa: 
expression in M CF-7 cells but will induce ERa: expression in T -4 7D and ZR-7 5-1 cells, 
each of which are breast carcinoma cell lines [Vienonen, et al., 2003]. Ngwenya, et al., 
2003, found that although ZR-75 and MCF -7 cells (bothER-positive breast cancer cell 
lines) use the same cis-elements and transcription factors to regulate hormone-dependent 
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regulation ofE2F-l gene expression, they do so through different mechanisms. If such 
significant differences occur in ER-positive breast cancer cell lines, then the differences 
between breast and kidney cells may be even greater. hMI-ERl may also have alternate 
functions, or alternate interaction partners, in normal versus cancer cells. It will, 
therefore, also be important to repeat experiments conducted in this study in a number of 
other normal and cancer cell lines in order to determine that interactions observed here 
are not specific to M CF -7 and HEK 293 cells and in order to further characterize the in 
vivo interaction between hMI-ERl a or hMI-ERl P and ERa in normal and neoplastic 
states. 
4.2.2 Punctiona{ Consequences of an Interaction 6etween fi:MI-P/1{.1 andP/1{.0 
In order to determine jfthe in vivo interaction between hMI-ERla or P and ERa 
would affect the genomic function of ERa, MCF-7 cells were co-transfected with a 
reporter construct containing three copies of the vitellogenin A2 (vitA2)-estrogen 
response element (vERE(3)TkLuc) and with hMI-ERla or p. Results from two 
independent experiments revealed that, while hMI-ERla did not appear to have any 
effect on ERE-driven transcription, hMI-ERlP enhanced ERE-driven transcription 
approximately three fold (Figures 21 and 24). 
Tk contains several Spl sites in its promoter and previous studies have found that 
hMI-ERl can function as a transcriptional repressor through interactions at Spl sites 
[Karlseder, et al., 1996; Paterno, et al., unpublished data]. In order to verify that results 
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A. Interaction between hMI-ERlJl and ERa in the absence of E2. 
ER a becomes activated by MAPK 
• ERa releases corepressor and recruits coactivators 
ERa./hMI -ERl containing 
coactivation complex 
B. Interaction between hMI-ERlJl and ligand-bound ERa. 
ERa./hMI-ER l containing 
coactivation complex with 
additional activator proteins 
Figure 24: Models demonstrating transactivation of ERE through interaction with 
hMI-ERl Jl-containing coactivation complexes. 
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DNA 
obtained with the vERE(3)TkLuc reporter construct were not altered by the presence of 
the Tk promoter, transcriptional reporter assays were performed in MCF-7 cells with one 
of two luciferase reporter plasrnids: pS2-ERELuc (with a functional ERE) and pS2-
LlERELuc (mutated ERE). pS2 is an estrogen-responsive gene, with a 5' region flanking 
region containing a TATA box, CAA T box and a single imperfect ERE, that provides a 
model system for the study of estrogen-regulated genes [Kim, et al., 2000]. Expression of 
pS2 has been used as a marker of estrogen-responsiveness in ER-positive breast cancer 
cells, an indicator of disease progression, and a predictor of success of anti estrogen 
therapy [Nunez, et al., 1989; Schwartz, et al., 1991; Foekens, et al., 1990]. Schwartz, et 
al., 1991, suggest that patients withER(+) breast tumours expressing pS2 are more likely 
to respond to hormone treatment. The results obtained in the present study with pS2-
ERELuc and pS2-LlERELuc showed, once again, that hMI-ER1~ enhanced ERE-driven 
transcription, however, hMI-ERla repressed ERE-driven transcription (Figure 22A). 
The distinct amino acid sequences for a and~ C-termini ofhMI-ER1 indicated 
that there could be an alternate function for each isoform. The three isoforms ofMTA 
(MTA-1, MTA-2 and MTA-3), for example, display 60% homology in amino acid 
sequence, and as such, possess a number of functional similarities and differences 
[Kumar, et al., 2003]. Both MTA-1 and 2 specifically repress transcription through 
association with deacetylase activity, whereas MTA-3 does not [Yao, et al., 2003]. 
Notably, MTA-1 and 2 exist in two biochemically distinct protein complexes and, thus, 
likely have different functional properties [Yao, et al., 2003]. A shorter, naturally 
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occurring variant ofMTA1, MTA1s, has also been identified [Kumar, et al., 2002]. 
MTA1s is an LXXLL motif-containing protein that has been found to interact with, and 
sequester, ERin the cytoplasm, enhancing nongenomic functions ofER [Kumar, et al., 
2002]. 
Perhaps hMI-ERla and hMI-ERl~ possess dual, or alternate, 
activation/repression functions. NRC (nuclear receptor co-regulators), is one such dual-
function protein. NRC contains one copy of the LXXLL motif that interacts with nuclear 
hormone receptors and possesses potent N-terrninal (AD1) and C-terminal (AD2) 
activation domains, however, the C-terminus of the protein, containing the LXXLL-motif, 
appears to inhibit overall transcriptional activity [Mahajan, et al., 2000]. NSD1, a novel 
mouse nuclear protein, is another bifunctional coactivator and corepressor that contains a 
SET domain (motif found in several chromatin-modifying proteins), and separate 
repression and activation receptor interacting domains (NID-L and NID+L) [Huang, et al., 
1998]. NID-L will interact with unliganded LBDs ofRAR and TR and allow binding of 
these receptors with corepressors, whereas NID+L will interact with liganded RAR, TR, 
RXR and ER and allow for binding of coactivators and transcription factors [Huang, et 
al., 1998]. bMI-ER1 may also have alternate cell context, ligand and receptor-specific 
functions. Perhaps, in vivo interactions between hMI-ERla or~ and ERa are more highly 
complex that the in vitro results would suggest. hMI-ERl may interact withER through 
more than one motif and/or through novel chromatin remodeling complex( es ). 
hMI-ERl has been found to interact with HDACl complexes [Ding, et al., 2003], 
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however, early evidence also suggests that hMI-ER1 is also involved in HAT complexes 
[Blackmore, et al., unpublished data]. In the present study, hMI-ER1a was found to 
inhibit ERE-driven transcription. Previous studies have also shown that hMI-ER1a and P 
repress transcription through recruitment ofHDAC1 complexes as well as through 
interactions with Sp1 and interfering with DNA-Sp1 interactions [Ding, et al., 2003; 
Ding, et al., unpublished data]. Results presented here, however, suggest that hMI-ER1P 
functions to enhance ERE-driven transcription. Similar results were found with transient 
transfection assays involving CAT reporter plasrnids and Gal4 DBD (DNA-binding 
domain) plasmids fused to one of various regions ofXMI-ER1 [Paterno, et al., 1997]. 
The N- terrninus ofXMI-ER1 (aa 1-175) stimulated transcription 80-fold [Paterno, et al., 
1997]. Further characterization of this function in hMI-ERl must be explored in various 
cell lines, and under different conditions. 
hMI-ER1a and p may have alternate functions themselves, or, simply interact 
with different complexes or interaction partners that control their function. MICoA, for 
example, can increase E2-mediated stimulation of ERE activity on its own, however, 
interaction with coactivator PELP1 and HAT will significantly increase this effect 
[Mishra, et al., 2003]. Interaction between MICoA and MTA-1 and HDAC2, on the other 
hand, will suppress MICoA-mediated stimulation ofERE activity [Mishra, et al., 2003]. 
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4.3 Puture Stuazes: 
A more complete understanding ofER-mediated transcriptional regulation is 
required for prevention and better treatment ofER-related diseases involving tissues such 
as breast and bone as well as in the urogenital and cardiovascular systems. It is now 
evident that hMI-ERl plays a role in the functioning ofER, however, further studies will 
be required in order to further characterize the structural and functional implications of 
this interaction. 
1. Examine subcellular localization of hMI-ERla/~ and ERa. 
Other than the traditional nuclear ER, biochemical, immunohistological and 
genetic methods have also established the existence of functional membrane and 
cytoplasmic ERs [Levin, 2002; Levin, 2001]. Studies conducted in our lab have been 
identified a functional NLS in the C-terminal domain ofXMI-ERl(NLS4) [Post, et al., 
2001]. Transfection assays with NIH 3T3 cells revealed that XMI-ERl translocated 
exclusively to the nuclei [Paterno, et al., 1997], whereas immunohistochemical studies of 
Xenopus laevis embryos revealed that XMI-ERl is found exclusively in the cytoplasm 
during early developmental stages but will progressively accumulate in the nuclei 
[Luchman, et al, 1999]. Analysis of the~ isoform ofhMI-ER1 revealed that it is the 
human orthologue ofXMI-ERl. Further analysis ofhMI-ERl a. and p revealed that hMI-
ERl p is targeted exclusively to the nucleus, likely due to a functional NLS, whereas hMI-
ER1a., which lacks an NLS, remained cytoplasmic [Paterno, et al., 2002]. These results 
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do not, however, rule out the possibility that bMI-ERla could be transported into the 
nucleus through interaction with other proteins, such as HDAC or nuclear hormone 
receptors. Techniques such as immunohistochemistry or confocal microscopy could be 
employed in order to determine the pattern of subcellular localization ofhMI-ERlcx., hMI-
ERl ~ and ERa. in the presence and absence of E2, which would help in determining 
whether hMI-ER could influence both the genomic and nongenomic actions ofER. 
2. Identify the region of ER responsible for interaction with hMI-ERl. 
Determining the region of ERa responsible for the interaction with hMI-ERla 
and~' will aid in developing a more complete understanding of the nature of the 
interaction between these proteins. In vitro work, such as GST pull down assays could be 
conducted, as described in Materials and Methods, using with GST-ERcx. deletion 
constructs. Co-transfection assays with deletion mutants of ERa. and full length bMI-
ERl ex or ~ would also help to further understand the nature of in vivo interactions. 
3. Examine the role of the LXXLL-motif in hMI-ERla. 
Although the LXXLL-motif ofhMI-ERl ex is not responsible for the interaction 
with ERa., this motif may be involved in the interaction ofhMI-ERlcx. with other proteins 
and may influence the functioning ofhMI-ERlcx. as an ERa. cofactor, as evidenced from 
the alternate function ofhMI-ERla and hMI-ERl~ in ERE-driven transcription. Site 
directed mutagenesis of one or more of the leucines in this motif, followed by transfection 
of the mutated hMI-ERl a., could help to identify a possible role for this motif in vivo. 
4. Examine the effect of other selective estrogen receptor modulators (SERMs) or 
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ligands on the interaction between ERa and hMI-ERl. 
Overexpression of ERa has often been observed in the early stages of breast 
cancer, therefore, hormone therapies have played a critical role in breast cancer 
management. Since estrogen plays in role in promoting growth and, thus, progression of 
breast cancers, anti-estrogens, or selective estrogen receptor modulators (SERMs), are 
widely used as anti-cancer therapies to modulate the function ofER. The transcriptional, 
or genomic, activity of ERa and ERP are influenced by both ligands and by coregulator 
proteins. Various ER ligands have demonstrated differences in their ability to recruit 
coregulators, indicating that various ligands can induce different ER conformations 
[Kraichely, et al., 2000]. Conformational differences will therefore not only affect 
recruitment of coregulators but will also have functional consequences for the receptor. 
For example, Schurr, et al., 2001, demonstrated an estrogen-dependent interaction 
between ERa and the proapoptotic forkhead transcription factor, FKHR, and showed that 
this interaction increased ERa transactivation through an estrogen response element. The 
interaction was found to be significantly reduced in the absence of hormone or in the 
presence of the anti-estrogen, tamoxifen. 
ER subtypes also will exert different cellular functions, depending on the nature of 
the bound ligand. As previously mentioned, ERa and ERP have been shown to interact 
with API transcription factors at API sites. In a study conducted in HeLa cells, ERa 
stimulated an APl -mediated transcription in the presence of estrogen whereas ERP 
demonstrated AP 1-mediated activation in the presence of anti estrogens [Paech, et al., 
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1997]. It would be interesting to determine whether the interaction between hMI-ERla or 
hMI-ERlP and ERa would be affected by various SERMs or anti-estrogens. 
5. Examine the possibility that hMI-ERl has other interaction partners. 
As evidenced from numerous studies referenced here, the ER requires interaction 
with multiple proteins in order to regulate its function. As previously mentioned., REA is 
a potent repressor ofER activity, however, interaction with prothymosin-a (PT-a) will 
recruit REA away from ER, and thereby allow for proper coactivation of ER [Martini, et 
al., 2000]. Indeed, preliminary studies have already demonstrated an interaction between 
hMI-ERl and HDACl, HAT, Spl, retinoblastoma (pRB), heat shock protein 40 (Hsp40), 
TRABID and core histone proteins [Ding, et al., 2003; Blackmore, et al., unpublished 
data; Paterno, et al., unpublished data]. Binding ofhMI-ERl to any one of these proteins 
could competitively affect its binding to another interaction partner, ultimately leading to 
the formation of multiple protein complexes, or, alternately, hMI-ERl may form one 
single complex with all of the above. 
Studies could be completed to further examine these possibilities, including a 
mammalian two hybrid screen, which detects protein-protein interactions in mammalian 
cells, and chromatin immunoprecipitation (ChiP) assays, which is a type of gene 
expression profiling involving the immunoprecipitation of transcriptionally active 
chromatin. The latter would help to characterize transcription complexes bound to ER-
target genes and would involve three steps: 1. in vivo formaldehyde cross-linking of 
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whole cells that freezes protein-protein and protein-DNA interactions, 2. 
immunoprecipitation of protein-DNA complexes, with antibodies such as anti-hMI-
ERla-specific, anti-hMI-ERl~-specific or anti-ERa, from cell extracts and, 3. use 
quantitative PCR or Southern Blot to analyze irnmunoprecipitates. This procedure would 
help to identify members ofhMI-ERla/ERa and/or hMI-ERl~/ERa protein complexes 
and to identify genes targeted by such complex( es ). 
6. Examine other functional consequences of the interaction between hMI-ERl and 
ERa, other than just an effect on ERE-driven transcription. 
Evidence suggests that estrogen receptors responsible for the nongenomic action 
of estrogen may be a form of classic ER, or possibly a short translational variant of ERa, 
found in the cytoplasm and plasma membrane [Li, et al., 2003; Figtree, et al., 2003; 
Anderson, 1998]. ERa located in the plasma membrane has been found to physically 
associate with, and activate, insulin-like growth factor receptor following E2 treatment 
[Kahlert, et al., 2000]. Estrogen can also activate phosphorylated membrane ER and, 
through G-proteins c-Src and matrix metalloproteinases, subsequently phosphorylate and 
activate HER2 [Razandi, et al., 2003]. The interaction between ERa and HER2 prevents 
tamoxifen-induced apoptosis in HER2 overexpressing breast cancer cells [Chung, et al., 
2002]. A number of these interactions lead to the activation of key downstream 
pathways, such as the MAPK pathway, that will subsequently activate transcriptional 
activity ofER and other components of the transcriptional machinery, thus linking the 
genomic and nongenomic actions of ER [Schiff, et al., 2004]. 
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It would be of great interest to determine if the interaction between hMI-ERla; or 
hMI-ERlP and ERcx would affect nongenornic functions ofER as opposed to genomic 
functions, such as ERE-driven transcription. For example, cotransfection experiments 
with hMI-ERla;/p and either wild type ERa;, ERa; with a membrane localization signal 
[MLS] or ERa; with an NLS could be completed. Cells would be treated with E2 or 
ethanol, and cell extracts could be run on an SDS gel. As discussed previously, ER 
located in the cell membrane has been found to induce MAPK activation, therefore, 
immunoblotting could be completed with an antibody specific for phosphorylated MAPK 
in order to determine if this signal cascade has been affected by the interaction between 
hMI-ERla; or p and ERa. 
7. Examine the interaction between hMI-ERl and other nuclear hormone 
receptors. 
Finally, it would also be useful to more fully examine the interaction ofhMI-
ERla; and hMI-ERlP with RARa;, RARP, RARy, RXRa; and RXRy in vivo, by 
employing procedures described in this study. It would also be useful to examine whether 
hMI-ERla; and P interact with any other nuclear hormone receptors, such as the 
glucocorticoid and androgen receptors. 
4. 4 Conclusion: 
The purpose of this study was to determine ifhMI-ERla; interacts with nuclear 
hormone receptors, through the LXXLL motif, and in doing so, affect the functioning of 
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nuclear receptors as transcription factors. Studies have revealed that both hMI-ERl a. and 
hMI-ERl p interact, in vitro, with ERa., RAR a., RARp, RAR y, RXRa. and RXR y and 
that the in vitro interaction between hMI-ERl a. or hMI-ERl p and ERa., RAR a., RARP is 
ligand independent. In vitro studies also indicate that amino acids within the region 325-
357 ofhMI-ERl are responsible for the interaction with ERa.,. 
In vivo studies, completed in MCF-7 cells, confirm an interaction between 
endogenous hMI-ERla. or hMI-ERlP and endogenous ERa., however, the exact nature of 
this interaction remains to be elucidated. Functional analysis in MCF -7 cells also 
revealed that hMI-ERl P enhances ERE-driven transcription whereas hMI-ERl a. will 
have no effect, or inhibit, ERE-driven transcription. This study confirms that hMI-ERl is 
indeed involved in ERa. actions in the cell, and as such, may have significant implications 
for the development of treatments for breast cancer. 
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6. Apoendices 
Table 1: PCR primer pairs used for preparing CS3-MT-hmi-erl constructs 
Construct Forward primer Reverse primer 
CS3-MT -hmi- 5'-CGGGATCCATATGGCG 5'-CGGGATCCAAAACAAG 
er1a GAGCCATCTGTTG-3' ACCACAGAAGC-3' 
aa 1-432 
CS3-MT-hmi- 5'-CGGGATCCATATGGC 5'-CGGGATCCTTAGTCATC 
er1P GGAGCCATCTGTTG-3' TGTGTTTTCAAG-3' 
aa 1 - 512 
[Ding, et al., 2003] 
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Table 2: PCR primer pairs used for constructing hMI-ERl and mutating hMI-ERl 
plasmids in pGEX-4Tl-1 vector 
Constructa Forward primer Reverse primer 
hmi-er1a 5' -CACCATGGCGACATCTG 5' -CGGGATCCAAAACAAGAC 
aa 1-433 TTGAATC-3' CACAGAAGC-3' 
hmi-er1~ 5' -CACCATGGCGACATCTG 5'-TCAATTAGTCATCTGTGTT 
aa 1-512 TTGAATC-3' TTCAAGTTC-3' 
aa 1-283 5' -CACCATGGCGACATCTG 5 '-AA TTCCTCTCTAGCTGCTT 
~4 TTGAATC-3' TTACA-3' 
aa 1-129 5' -CACCATGGCGACATCTG 5' -CCTTTATTAGGCGGGTGCA 
~5 TTGAATC-3' GC-3' 
aa 287-433 5' -CACCATGGTTTGGACAG 5' -CGGGATCCAAAACAAGAC 
~9 AGGAAGAGTGTA-3' CACAGAAGC-3' 
aa 325-433 5' -CACCATGGCATTCTATTA 5' -CGGGATCCAAAACAAGAC 
~10 CATGTGGAAAAAA TCT -3' CACAGAAGC-3' 
aa 355-433 5' -GTAACGGATTACATGGAT 5' -CGGGATCCAAAACAAGAC 
~11 CGTC-3' CACAGAAGC-3' 
aa 163-283 5' -GAAGAATCTGAAGAAGAT 5' -AATTCCTCTCTAGCTGCTT 
~13 GAAGATT-3' TTACA-3' 
aa 287-512 5' -CACCATGGTTTGGACAG 5' -CGGGATCCTTAGTCATCT 
~16 AGGAAGAGTGTA-3' GTGTTTTCAAG-3' 
aa 287-410 5' -CACCATGGTTTGGACAG 5' -CTGGTCCATTAGATGACA 
~17 AGGAAGAGTGTA-3' CTCCA-3' 
aa 287-357 5' -CACCATGGTTTGGACAG 5' -CCGTTACACCAGGATGAA 
~18 AGGAAGAGTGTA-3' GATT-3' 
aa 287-330 5' -CACCATGGTTTGGACAG 5'-CCACATGTAATAGAATGC 
~19 AGGAAGAGTGTA-3' TACA-3' 
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